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About the Health Information and Quality Authority  
The Health Information and Quality Authority (HIQA) is an independent authority 
established to drive high-quality and safe care for people using our health and social 
care services in Ireland. HIQA’s role is to develop standards, inspect and review 
health and social care services and support informed decisions on how services are 
delivered.  
HIQA aims to safeguard people and improve the safety and quality of health and 
social care services across its full range of functions.  
HIQA’s mandate to date extends across a specified range of public, private and 
voluntary sector services.  
Reporting to the Minister for Health and the Minister for Children and Youth Affairs, 
HIQA has statutory responsibility for:  
Setting Standards for Health and Social Services — Developing person-
centred standards, based on evidence and best international practice, for health and 
social care services in Ireland.  
Regulation — Registering and inspecting designated centres.  
Monitoring Children’s Services — monitoring and inspecting children’s social 
services.  
Monitoring Healthcare Safety and Quality — Monitoring the safety and quality 
of health services and investigating as necessary serious concerns about the health 
and welfare of people who use these services.  
Health Technology Assessment — Providing advice that enables the best 
outcome for people who use our health service and the best use of resources by 
evaluating the clinical effectiveness and cost effectiveness of drugs, equipment, 
diagnostic techniques and health promotion and protection activities.  
Health Information — Advising on the efficient and secure collection and sharing 
of health information, setting standards, evaluating information resources and 
publishing information about the delivery and performance of Ireland’s health and 
social care services.   
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Note on terms used in this document 
A full range of terms used in this document is contained in a glossary at the end of 
this report. 
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 Executive summary  
As modern medicine continues to advance, increasing medication treatment options 
are available for patients with proven benefit for treating illness and preventing 
disease. This advancement has brought with it an increase in the risks, errors and 
adverse events associated with medication use. While most medication errors do not 
result in patient harm, medication errors have the potential to result in catastrophic 
harm or death to patients in some instances.1   
Medication safety has been identified internationally as a key area for improvement 
in all healthcare settings. 2 In March 2017 the World Health Organization (WHO) 
identified Medication Safety as the theme of the third Global Patient Safety 
Challenge. This global safety initiative aims to address the weaknesses in health 
systems that lead to medication errors and the severe harm that may result. The 
WHO sets out its specific aim to ‘reduce the level of severe avoidable harm related 
to medications by 50% over 5 years globally’.3 This global safety initiative is also a 
key area for improvement in an Irish context.4,5  
HIQA’s medication safety monitoring programme, which commenced in 2016  aims 
to examine and positively influence the adoption and implementation of evidence-
based practice in public acute hospitals around medication safety. HIQA monitors 
medication safety against the National Standards for Safer Better Healthcare, to 
determine if public acute hospitals in Ireland have: 
§ the required governance arrangements at a foundation level in place to drive 
improvement in medication safety  
§ recognised medication safety as a priority at a senior management level with 
a medication safety strategy and appropriate support 
§ effective arrangements in place to protect patients from harm related to 
medication use, in line with international best practice and research 
§ the essential elements of a medication safety programme in place.  
From November 2016 to October 2017, 34 public acute hospitals were inspected as 
part of HIQA’s medication safety monitoring programme. HIQA identified that many 
Irish hospitals have performed very well in implementing medication safety 
programmes. Effective medication safety programmes were evident where there was 
leadership from chief pharmacists, supported by senior management, and effective 
reporting to clinical governance and patient safety structures. Inspectors also found 
examples of hospitals that had made considerable progress in medication safety in a 
short period of time. This involved collaboration and learning from the work and 
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efforts of other hospitals within hospital groups, but also in the wider context, for 
example specialist paediatric hospitals collaborated with regional general hospitals 
that provided paediatric services.  
However, HIQA found that several hospitals require further investment and or 
sharing of resources across their respective hospital groups to implement effective 
medication safety programmes. There was clear evidence that where appropriate 
resources have been provided, progress in implementing medication safety 
programmes had generally advanced. 
Of the 34 hospitals inspected, HIQA found that 30 had a Drugs and Therapeutics 
Committee in place, three hospitals had established links with another hospital’s 
Drugs and Therapeutics Committee and one hospital had no Drugs and Therapeutics 
Committee at the time of the inspection.  
HIQA found that 13 hospital’s Drugs and Therapeutics Committees were not 
functioning effectively and were required to strengthen their governance structures 
and processes to support medication safety. 
Six hospitals had medication safety strategies, outlining the future vision and 
direction in relation to improving safety with medicines. Other hospitals inspected 
had a medication programme or plan, but one in three hospitals had no formal 
strategy or plan to direct medication safety improvement activities.  
Formularies* and systems for evaluating new medicines using written criteria and 
multidisciplinary oversight was in place in 13 hospitals, with all new medicines 
approved by the Drugs and Therapeutics Committee. The other 21 hospitals did not 
have a formulary in place, but had a stock list or inventory of medicines. These 
hospitals were advised by HIQA at the time of inspection that they should consider 
the development of a defined formulary, or collaborate with other hospitals to 
facilitate the use of a shared medicines formulary.   
There is currently no national strategy or standards outlining requirements for the 
provision of clinical pharmacy services in Irish hospitals as recommended by a multi-
agency review of hospital pharmacy services in Ireland in 2011.6 HIQA found 
disparities in clinical pharmacy services, both in how they were provided and in the 
resources allocated to them. The clinical pharmacy service in five of the hospitals 
                                       
* A formulary is a managed list of preferred medicines that have been approved by the hospital’s 
Drugs and Therapeutics Committee for use at the hospital. Use of a formulary ensures governance 
oversight of the introduction and ongoing use of medicines in practice at the hospital, and in doing so 
ensures an appropriate level of management control over medicines use, in the interest of both 
patient safety and financial management. 
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inspected was almost entirely confined to dispensing,† one of these five hospitals 
was reliant on a nearby hospital to provide clinical pharmacy services.  
Clinical pharmacy provision to paediatric and maternity services in some regional 
hospitals was generally offered as reactive rather than as a continuous service. The 
limited and incomplete clinical pharmacy cover in paediatric and maternity services, 
including Paediatric and Special Care Baby Units, in a number of regional public 
acute hospitals was of concern to HIQA. International evidence on medication errors 
indicates that a small error in dose of medication given to children has a greater risk 
of harm compared with the adult population.7 
Practice related to medicines reconciliation‡ in hospitals during transitions of care 
was also found to be varied. Three of the 34 hospitals inspected conducted 
medication reconciliation on admission and discharge. Thirteen hospitals had 
implemented medication reconciliation on admission. Eight hospitals had a clinical 
pharmacist in their emergency department to support medication reconciliation on 
admission.  
Some developments had been made to introduce smart technology and eHealth to 
the medication management process such as electronic prescribing, electronic 
medication reconciliation, automated dispensing as well as information 
communication technology (ICT) solutions to stock control and ordering of medicines 
at ward level. Many of these projects were only at pilot phase at the time of 
inspection, but the future potential for efficiency and improved safety through 
innovative use of technology is supported by HIQA in line with international research 
and best practice.  
HIQA found that all hospitals inspected had some systems in place to support the 
provision of patient information and education in relation to medication use. Clinical 
pharmacists were usually available to provide information to patients on request 
from clinical staff and some hospitals demonstrated good examples of patient 
information and education, in particular specialist and paediatric hospitals. However, 
the processes in place for providing patients with information about their medicines 
varied between hospitals. Some patients received structured education by an 
appropriate clinician, clinical pharmacist or other healthcare professional, supported 
by individualised written information, while other patients reported that they did not 
receive information about new medicines they were prescribed. 
                                       
† Dispensing involves the preparation, packaging, labelling, record keeping, and transfer of a 
prescription medication to a patient or an intermediary (such as a nurse or doctor), who is 
responsible for administration of the medication. 
‡ Medication reconciliation is a systematic process to obtain an accurate and complete list of all 
medications taken prior to admission, discharge and other transitions in care. 
Medication safety monitoring programme overview report 
___________________________________________________________ 
Health Information and Quality Authority 
 
8 
 
HIQA conducted an anonymous patient questionnaire with 444 patients who had 
been inpatients in hospital within the past year and were discharged on regular 
medicines. Over half (58%) of patients reported that a member of staff explained 
newly prescribed medicines in a way they could completely understand, with an 
additional 16% reporting new medicines were explained to some extent. One in 10 
patients reported that the purpose of their new medication was not explained. The 
remaining sixteen percent responded that they hadn’t started new medicines or 
didn’t require an explanation. These findings broadly reflected findings from the 
recent National Patient Experience Survey§.8 
Most hospitals had policies, procedures, protocols, guidelines and access to 
information at the point of care to support medication safety. This had been 
enhanced in some hospitals through sharing and collaboration between hospitals 
and the use of mobile technology for access to medicines information at the point of 
prescribing and administration. However, inspectors found in a small number of 
cases, medicines information sources were not designed for use in that hospital and 
were not overseen and approved for use by the hospitals Drugs and Therapeutics 
Committee. This could pose a risk if a medicine, although used correctly, was used 
in the wrong clinical setting. 
Hospitals with well-established medication safety programmes had systems of 
assurance in place regarding medication safety including; proactive risk assessment, 
monitoring against international standards and best practice, and quality 
improvement monitoring. Two hospitals had planned medication safety audits that 
were aligned to their overall medication safety strategy. 
It is estimated that at least one medication error occurs per hospital patient each 
day.9 Internationally, hospitals face challenges with underreporting of medication 
errors as part of incident reporting systems.10 All hospitals inspected had incident 
reporting systems in place, but inspectors found that many hospitals had significant 
under-reporting of medication safety incidents. Incident reporting systems were 
mainly supported in hospitals by clinical pharmacists and nurses. 
HIQA found that five hospitals had a comprehensive, ongoing medication safety 
training programme for clinical staff. Almost all hospitals had medication 
management education sessions for nurses and doctors on induction, with some 
hospitals providing structured, ongoing medication safety training programmes. 
However, there was a lack of planned and structured ongoing training for clinical 
                                       
§ The National Patient Experience Survey was a nationwide survey which asked people for feedback 
about their stay in hospital. The survey was a partnership between the Health Service Executive 
(HSE), HIQA and the Department of Health. All adult patients discharged during May 2017 who spent 
24 hours or more in a public acute hospital, and have a postal address in the Republic of Ireland were 
asked to complete the survey. 
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staff in relation to medication safety in many hospitals, with potential scope for 
improvement consistently identified throughout this monitoring programme. 
HIQA identified areas of high risk in six hospitals, four were in relation to the 
governance of medication safety, one was in relation to intravenous monographs 
and one was in relation to accommodating paediatric patients in a room with 
unsecured access to medications. These risks were brought to the attention of 
hospital managers at the time of the inspection in line with HIQA’s escalation 
process. HIQA sought assurance that improvements would be made in a timely 
manner to mitigate the risks identified to ensure patient safety. Improvements in 
these hospitals governance structures and processes around medication safety need 
to be prioritised to bring medication safety up to the level necessary to ensure 
patient safety.  
A variety of medication safety quality improvement initiatives were demonstrated 
during this programme and some examples are highlighted throughout this report. 
Many of these were based on risk reduction strategies and learning from medication 
incidents. In addition, some quality improvement initiatives were as a result of 
collaboration with other hospitals. While collaboration between hospitals is 
happening, a greater focus on collaboration at a hospital group and national level 
would reduce duplicated effort, and lead to faster progression in driving collective 
improvement. This is essential to ensure that errors with the use of medicines are 
not repeated, and above all so that patients do not suffer harm from known and 
potentially avoidable errors. 
Furthermore, this should be supported by strategic planning for medication safety at 
a hospital group and national level. In addition, a national coordinated response is 
required to progress innovations with technology and information systems in order 
for significant improvement to occur in medication safety 
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Key recommendations 
Key recommendations from HIQA medication management monitoring programme 
are listed below. They are separated into recommendations with a national focus 
and those focused on improving medication safety in hospitals. 
 
Recommendations focused on improving medication safety at a national 
level 
1. At a national level, efforts to enhance learning from medication incidents and 
quality improvement initiatives should be put in place. This should include 
reviewing research in relation to medication safety, both nationally and 
internationally, to proactively address medication related risk. 
2. Centralised arrangements should be put in place to ensure good practices that 
HIQA has reported through these series of inspection are shared.  
3. A national plan for the development of comprehensive clinical pharmacy services 
that sets out the desired model of care, and the appropriate resources to ensure 
consistency across hospitals should be developed. 
4. Develop a national approach to advance medication reconciliation to include 
defining responsibility for medication reconciliation and using electronic solutions 
to reduce time spent by clinical staff on medication reconciliation. 
5. Utilise information technologies such as ePrescribing, smart pump technology 
and decision support tools to reduce medication incidents and risks. At a 
national level hospital groups should work together to commence the 
implementation of electronic solutions to improve medication safety. 
 
Recommendations focused on improving medication safety in hospitals 
6. Hospitals must have formalised governance structures with clear accountability 
and responsibility arrangements to support medication safety. This includes a 
functioning Drugs and Therapeutic Committee with clear terms of reference and 
membership to provide assurance that medication management systems are 
safe.  
7. The Drugs and Therapeutics Committee should have a clear strategic plan for 
improving medication safety outlining short, medium and long-term goals, with 
a supporting time bound medication safety programme or plan.  
Medication safety monitoring programme overview report 
___________________________________________________________ 
  Health Information and Quality Authority 
 
11 
 
8. Hospitals should have a defined formulary process to outline medicines that are 
approved for use in the hospital, and provide information and standard guidance 
on the use of these medicines.  
9. Hospitals should build patient education requirements into the medication 
management process, based on services provided and their patient population, 
to ensure patients and or care givers are given the appropriate medicines-
related information.  
10. Hospitals should provide clinical staff with easily accessible information and or 
policies, procedures, guidelines and or protocols to guide the safe use of 
medicines at the point of prescribing, preparation and administration.  
11. Hospitals should support a culture of reporting medication related incidents and 
near misses among all healthcare professionals. Data from medication incidents 
should be routinely analysed to identify trends or patterns in relation to risk and 
identify areas that require targeted improvement.  
12. Hospitals must ensure healthcare professionals have the necessary 
competencies to deliver high-quality medication safety through induction and 
ongoing training. This should include a structured, targeted programme of 
education for medication safety aligned with the hospitals medication safety 
strategy.  
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Role of the Health Information and Quality Authority  
HIQA was established in 2007 to promote safety and quality in the provision of 
health and social care services for the benefit of the health and welfare of the public. 
Under section 8(1) (b) of the Health Act 2007,11 HIQA has, among other functions, 
the role of setting standards on safety and quality in relation to services provided by 
the Health Service Executive (HSE) or a service provider in accordance with the 
Health Acts 1947 to 2007. 
Under section 8(1) (c) of the Health Act 2007, 11 HIQA also has the function to 
monitor compliance with standards and to advise the Minister for Health and the 
HSE as to the level of compliance of service providers with the standards. 
The role of standards and continuous monitoring in improving 
quality and safety in healthcare 
The National Standards for Safer Better Healthcare 12 (referred to in this guide as 
the National Standards), which are available to view on HIQA’s website www.hiqa.ie, 
took effect from June 2012. The National Standards aim to help promote 
improvements in the quality and safety of healthcare services in Ireland. Their 
purpose is to help the public, people who use healthcare services and the people 
who provide them to understand what a high-quality safe healthcare service should 
look like.  
The National Standards contain 45 standards presented under eight themes as 
shown in Figure 1. Collectively, these standards describe how a service provides 
high-quality, safe and reliable healthcare which is centred on the patient. To deliver 
high-quality, safe and person-centred care that promotes the individual’s health and 
wellbeing, there needs to be certain capacity and capability factors in place to 
ensure the sustainability of the service.  
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Figure 1. Diagrammatic representation of the themes in the National Standards for Safer 
Better Healthcare 
Themes one to four of the National Standards describe the dimensions of quality and 
safety in the delivery of a person-centred healthcare service.  
§ Theme 1: Person-centred Care and Support  
§ Theme 2: Effective Care and Support  
§ Theme 3: Safe Care and Support  
§ Theme 4: Better Health and Wellbeing.  
Themes five to eight of the National Standards describe the capacity and capability 
factors necessary to deliver high-quality, safe care.  
§ Theme 5: Leadership, Governance and Management  
§ Theme 6: Workforce  
§ Theme 7: Use of Resources  
§ Theme 8: Use of Information  
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International experience shows that implementing evidence-based standards in 
healthcare settings, together with continuous monitoring of compliance with these 
standards, is a crucial quality and safety improvement measure.13,14 It is the role of 
each hospital to assure itself, its patients and the public that it is providing safe, 
high-quality care by demonstrating that it is meeting the National Standards at all 
times.  
HIQA, through its monitoring programmes, aims to assure the public that hospitals 
are implementing and meeting the National Standards12 and are making any 
necessary quality and safety improvements that are required to safeguard patients.  
To achieve this, HIQA designed an evidence-based monitoring programme targeted 
at medication safety and underpinned by the National Standards12 to examine if 
public acute hospitals have the essential capacity and capability factors in place to 
improve patient safety related to medication use.  
This medication safety monitoring programme is aligned to HIQA’s mission to 
promote safety and quality in the provision of health and social care services for the 
benefit of the health and welfare of the public and operates within HIQA’s core 
values. 
 
  
Medication safety monitoring programme overview report 
___________________________________________________________ 
  Health Information and Quality Authority 
 
15 
 
Our mission 
The mission of HIQA is derived from the statutory functions described in the Health 
Act 200711 and can be summarised as:  
“Drive high-quality and safe care for people using our health and social 
services.” 
 
Our values  
§ Putting people first — we will put the needs and the voices of patients, and 
those providing them, at the centre of all of our work.  
§ Fair and objective — we will be fair and objective in our dealings with people 
and organisations, and undertake our work without fear or favour.  
§ Open and accountable — we will share information about the nature and 
outcomes of our work, and accept full responsibility for our actions.  
§ Excellence and innovation — we will strive for excellence in our work, and 
seek continuous improvement through self-evaluation and innovation.  
§ Working together — we will engage with people providing and people using 
the services in developing all aspects of our work.  
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1. Background 
Medicines play an essential role in the treatment of illness, managing chronic 
conditions and maintaining health and wellbeing. Many of the advances in life 
expectancy and improved patient quality of life that have been experienced over the 
past few decades are attributed to advancements in the availability and use of 
medicines. Increased choice of treatments, including the use of high-risk medicines 
adds complexity, and medication safety needs to be understood in relation to 
increasingly complex health systems as new treatments can involve multiple 
medicines and higher risk of medication errors.15 
Extensive international research has identified medication use as the leading cause 
of unintended harm for patients availing of hospital care.3,16,17,18 The Institute of 
Medicine estimated that on average at least one medication error per hospital 
patient occurs each day.9 This figure would potentially equate to over three million 
medication errors in Irish public hospitals per year.19 Medication incidents, errors, 
and adverse drug events are terms that have been used to refer generally to 
describe harm caused by medicines occurring during the medication management 
process**.16  
It is estimated that the majority of medication errors could be potentially 
preventable. However, the true number of medication errors is difficult to determine, 
as many errors are never discovered, acknowledged or reported.20 Most medication 
errors cause little to no actual harm to patients, and some are unavoidable through 
unforeseen circumstances.21 Nonetheless, medication errors have in some instances 
the potential to result in catastrophic harm or death to patients.22  
Medication safety has been identified by a number of bodies in Ireland as a key 
focus for improvement to prevent or reduce medications incidents.23,24,25,26,27,28 A 
national clinical incident five-year review from 2010 to 2014 in Ireland found that 
medication incidents accounted for 14.7% of the ten most common reported 
incidents. These medication incidents related to incorrect dosage, missed medication 
and incorrect or not reconciled medication.5  
Medication errors occur when weak medication safety systems are in place and or 
human factors such as fatigue, poor environmental conditions or staff shortages 
impacts on any stage of the medication management process.16   
While those with responsibility for prescribing medicines need to balance the 
benefits of using a chosen medicine against the risks for patients, in some instances 
                                       
** The medication management process includes selection, procuring, storing, ordering, prescribing, 
transcribing, distributing, preparing, dispensing, administration documentation, reconciliation, 
monitoring and disposal of medicines. 
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patients may experience adverse effects from medication use due to expected or 
unexpected side-effects.16  In addition, where medicines are used, the potential for 
error in use also exists, for example in prescribing, administrating, monitoring, or 
using in combination with other incompatible medicines.  
Medication safety programmes have been introduced in many hospitals to try to 
minimise the likelihood of harm associated with the use of medicine, and in doing so 
maximise the benefits for patients. These programmes aim to drive best practice in 
medication safety by working to encourage a culture of patient safety at all levels in 
the organisation, and through the introduction of systems and processes that 
prevent and or reduce the impact of medication-related risk.29,30 
Traditional medication safety programmes have focused on changing individual 
behaviour using education, policies and procedures, and disciplinary action to 
improve compliance with policies and procedures.31 However, it is now generally 
accepted that medication safety programmes must take a systems-oriented 
approach rather than the traditional person-centred approach that focuses only on 
increasing the vigilance of those working in healthcare.32 Medication safety 
programmes should be directed towards standardising practices and systems to 
reduce unnecessary variation, along with effective use of resources to enhance 
knowledge and skills. In addition, medication safety programmes should strive to 
develop a patient safety culture with senior leadership support, continuous 
operational training for front-line staff and high-level organisational learning from 
incidents.16  
Medication safety programmes, as with all patient safety programmes, should be 
underpinned by accountability and governance arrangements to ensure effective 
oversight of medication use and safety within hospitals. Furthermore, hospitals 
should have a clear strategic plan for medication safety to support a medication 
safety programme. Medicines-related policies and procedures must be in place to 
ensure patients are not unduly exposed to clinical risk or harm from medication 
use.33  
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2. Introduction to findings from on-site inspections 
An evidence-based monitoring programme, which involved announced inspections of 
public acute hospitals in Ireland, was developed by HIQA to examine and analyse 
systems in place to support safe medication practice in line with international best 
practice and research. HIQA carried out 34 announced on-site inspections to 
evaluate the structures and systems in place to support medication safety.  
HIQA’s monitoring programme aims to establish if hospitals have the essential 
elements of a medication safety programme in place, with a particular focus on: 
§ governance of medication safety,  
§ medication safety support structures and processes, 
§ person-centred care, 
§ policies, procedures and guidelines and information to support medication 
safety,   
§ risk management and incident reporting, 
§ evaluation and audit of medication safety,   
§ training and education.  
Inspections were carried out to determine if hospitals had effective and safe 
medication management systems in place to ensure patient safety in line with 
international best practice and research.  
This report sets out the findings from 34 hospital inspections as part of HIQA’s 
medication safety monitoring programme from October 2016 to November 2017. 
The purpose of this overview report is to collate the findings, both to highlight good 
practice seen on inspections and to elicit where improvements should be made to 
improve safety with the use of medicines in public acute hospitals in Ireland.  
All 34 hospitals inspected are listed in Appendix 1 and individual hospital reports, 
previously published, are available on the HIQA website www.hiqa.ie. The 
methodology, lines of enquiry and process for onsite inspections used by HIQA in 
this medication safety monitoring programme, are set out in detail in Appendix 2. 
The findings outlined in this report focus on the essential elements of a medication 
safety programme. Areas of good practice observed in hospitals inspected are 
highlighted throughout the report to support learning and collaboration, and 
recommendations for improvement across the wider healthcare system supporting 
medication safety are included at the end of each section.  
During the course of the 34 inspections, HIQA identified specific high risks in six 
hospitals as listed below: 
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§ Bantry General Hospital,  
§ Letterkenny University Hospital,  
§ Midland Regional Hospital Mullingar,  
§ St Luke’s General Hospital Kilkenny,  
§ University Hospital Limerick,  
§ University Hospital Waterford.  
Risks were primarily identified in relation to the governance of medication safety and 
were brought to the attention of the Senior Management Team in the hospitals at 
the time of inspection. Subsequently, formal written notification of the identified 
risks was issued to the accountable person†† in each hospital within two working 
days of the inspections. Hospitals were required to formally report back to HIQA with 
an action plan to reduce and effectively manage the risks identified within five 
working days of receipt of the written notification.  
A summary of the risks identified during inspections, as well as the process for risk 
escalation and identification are outlined in Appendices 3, 4 and 5. Details of the 
risks identified were included in the hospitals published medication safety inspection 
reports, along with copies of correspondence between HIQA and the hospitals.  
As part of its assessment, HIQA included an opportunity for patients to provide 
insight into their experience of the medicines information given to them. During the 
course of the inspections, hospitals were requested to distribute a short, anonymous 
paper questionnaire to a number of patients in their outpatient department.  
The purpose of the questionnaires was to gather key information about the advice 
and information patients received in relation to their medication, while in hospital 
and at the point of discharge. Questionnaires were distributed to patients who had 
been inpatients in the hospitals within the past year and who were prescribed 
regular medications. A total of 444 patients completed the questionnaires 
throughout the 34 hospitals inspected. The patient questionnaire and results are 
outlined in more detail later in this report.  
HIQA would like to thank the patients who took the time to complete questionnaires 
and would like to acknowledge the cooperation and assistance of hospital staff who 
participated in the on-site inspections. 
                                                                                                                                                                              
                                       
†† Accountable person: is the identified individual or individuals with overall executive accountability, 
responsibility and authority for the delivery of high-quality, safe and reliable services. 
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2.1 Governance of medication safety 
Line of enquiry:  
Ø Patient safety is enhanced through an effective medication safety programme 
underpinned by formalised governance structures and clear accountability 
arrangements. 
The National Standards state that a well-governed service is clear about what it 
does, how it does it, and is accountable to its stakeholders, including the people who 
use the services.12 To comply with the National Standards in relation to medication 
safety, health service providers are responsible for ensuring that effective 
governance structures are in place in relation to all stages of the medication 
management process. Therefore, the first phase of HIQA’s medication safety 
monitoring programme focused on how management structures and accountability 
arrangements were configured in public acute hospitals to promote governance and 
oversight of medication safety including risks relating to medicines.   
Governance structures and Drugs and Therapeutics Committees 
International evidence outlines that the medicines management system of each 
hospital should be under the governance of a committee such as a Drugs and 
Therapeutics Committee.34 This Committee should be multidisciplinary‡‡ with 
responsibility for the overall governance and oversight of the medicines 
management system. The Drugs and Therapeutics should have clear terms of 
reference outlining its role and function with formalised reporting structures to the 
organisation’s executive and clinical governance committees. In addition, hospitals 
should have a medication safety strategy with an operational medication safety plan 
aligned to the hospital’s overall strategic goals.12   
The scope and function of a Drugs and Therapeutics Committee may vary depending 
on local requirements and structures.33 The Drugs and Therapeutics Committee is 
the advisory Committee on medication management for the hospital and its 
functions include: 
§ evaluating and selecting medicines for use within the hospital (formulary), 
§ monitoring and evaluating medicine use to identify problems through 
medication incidents reports, audit and evaluation, 
                                       
‡‡Multidisciplinary: an approach to the planning of treatment and the delivery of care for a service 
user by a team of healthcare professionals who work together to provide integrated care. 
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§ monitoring of medication incidents and adverse drug reactions, 
§ quality improvement interventions to improve medicine use, 
§ providing oversight of devices and technologies used in medicines 
management, 
§ reviewing and approval of medication policies, procedures and guidelines and 
all information sources in use,  
§ educating and sharing information,  
§ involvement in monitoring and evaluating the risks of clinical trials. 
Organisational charts which outlined how Drugs and Therapeutics Committees fitted 
into the overall accountability arrangements of hospitals were requested and 
provided to HIQA in advance of inspections. Typically inspection teams found that 
Drugs and Therapeutics Committees were part of the hospital’s overall clinical 
governance structure and reported to the Quality, Safety and Risk Committee (or 
equivalent), which in turn reported to hospital’s Executive Committees.  
Overall, HIQA found that hospitals that had well-established governance structures 
(such as a Drugs and Therapeutic Committee), with support from senior hospital 
management and effective clinical pharmacy leadership, were more likely to have 
identified medication safety as a key priority area and have an effective medication 
safety programme in place (Figure 2). Inspectors also found that senior 
management and clinical leaders in higher performing hospitals had invested 
dedicated resources to medication safety and clinical pharmacy services over a 
number of years. In hospitals where this had not occurred approaches to improve 
medication safety were more fragmented.  
 
 
Figure 2: Effective medication safety programmes 
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Many hospitals’ Drugs and Therapeutics Committees had additional subcommittees 
or working groups reporting to them that were set up to dedicate more time and 
expertise on specific areas of medication safety. Subcommittees covered aspects of 
medication safety including medication safety, antimicrobial stewardship, nurse 
prescribing and drug evaluation and formulary management. 
Medication Safety Committees were set up to oversee medication safety 
programmes in 19 out of the 34 hospitals inspected. Some hospitals had only 
recently set these up at the time of the inspection, so they were at the early stages 
of development. HIQA concluded that while some hospitals had established 
Medication Safety Committees, it is not an essential requirement to support 
medication safety. The strong focus placed on medication safety is commendable 
but hospitals need to ensure that each committee is an effective and efficient use of 
staff resources to avoid over burdening staff and duplication of effort.  Hospitals, 
depending on their model§§, size and structure, can support medication safety 
through other committees or systems as appropriate.35  
Almost one in four hospitals with well-established medication safety committees and 
programmes had employed specialist pharmacy staff in the role of dedicated 
medication safety officer. The vast majority of these were based in large Dublin 
teaching hospitals.  
HIQA identified variation in the presence and effectiveness of governance structures, 
such as Drugs and Therapeutics Committees. While some hospitals had strong and 
clear accountability arrangements for managing and improving medication safety, 
other hospitals had a lack of or fragmented governance structures in place to 
oversee medication safety.  
Of the 34 hospitals inspected, 21 had a functioning Drugs and Therapeutics 
Committee that was responsible for the overall governance and strategic leadership 
of medication management systems within these hospitals.33  Of the remaining 13 
hospitals:  
                                       
§§ The National Acute Medicine Programme model of hospitals involves four levels of acute hospitals 
in relation to acute medicine patients; 
Model-1 hospitals: are community and or district hospitals and do not have surgery, emergency care, 
acute medicine (other than a select group of low-risk patients) or critical care.  
Model-2 hospitals: can provide the majority of hospital activity including extended day surgery, 
selected acute medicine, local injuries, a large range of diagnostic services, including endoscopy, 
laboratory medicine, point-of-care testing, and radiology – computed tomography (CT), ultrasound 
and plain-film X-ray – specialist rehabilitation medicine and palliative care.  
Model-3 hospitals: admit undifferentiated acute medical patients, provide 24-seven acute surgery, 
acute medicine, and critical care.  
Model-4 hospitals: are tertiary hospitals and are similar to model 3 hospitals but also provide tertiary 
care and, in certain locations, supra-regional care. 
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§ one hospital had no Drugs and Therapeutics Committee, 
§ three model 2 hospitals had no Drugs and Therapeutics Committee, but had 
links with a Drugs and Therapeutics Committee within their hospital group***,  
§ nine hospitals had a Drugs and Therapeutics Committee, however these 
committees required strengthening of their governance and oversight 
arrangements with regard to medication safety.  
The hospital which had no Drugs and Therapeutics Committee on the day of 
inspection subsequently informed HIQA that it was planning to link into a Drugs and 
Therapeutics Committee in the model 4 hospital within their group.  
Three model 2 hospitals had links with a Drugs and Therapeutics Committees in a 
nearby tertiary hospital within their hospital group. Despite this link, there remained 
a lack of integration between these hospitals, resulting in a disjointed approach to 
leadership, governance, oversight and support for medication safety. For example, 
the governance arrangements in one of these hospitals were further complicated by 
ambiguity in relation to responsibility for medication safety at a corporate level. This 
was due to a legacy agreement, whereby the hospital was corporately and clinically 
managed by a large regional university hospital that was responsible for medication 
safety, while pharmacy services were provided by another local general hospital. 
Inspectors noted that two hospital groups had established a group wide Drugs and 
Therapeutics Committee at the time of the announced inspections to support 
collaboration about medication management at hospital group level.36 
Of the nine hospitals that needed to strengthen governance, four hospitals were 
found to have governance arrangements that were fragmented and underdeveloped 
due to a lack of leadership, resources and effective systems in place at the time of 
inspection to ensure the minimum standards of medication safety and quality were 
met. HIQA identified that these hospitals in particular needed to make significant 
improvements to the functioning of their Drugs and Therapeutics Committees.  
It was of concern that these four hospitals, some providing significantly complex 
clinical care, did not have adequate governance structures and clear accountability 
arrangements in place for medication safety. Therefore HIQA wrote to these four 
hospitals immediately after the inspection as part of HIQA’s risk escalation process 
seeking assurances that the hospitals were mitigating the composite of medication 
                                       
*** Hospital groups: The hospitals in Ireland are organised into seven hospital groups. 1. Ireland East 
Hospital Group. 2. Dublin Midlands Hospital Group. 3. South/South West Hospital Group4. Saolta 
Hospital Group. 5. University Limerick Hospitals Group. 6. RCSI Hospitals Group 7.National Children’s 
Hospital Group. 
Medication safety monitoring programme overview report 
___________________________________________________________ 
Health Information and Quality Authority 
 
24 
 
safety related risks identified by inspectors. Risks identified included a combination 
of some or all of the following risks:  
§ a lack of strategic and operational plans detailing the development, 
implementation and maintenance of hospital-wide medication safety systems,  
§ inadequate arrangements in place to identify, report and manage risks 
associated with medication use, 
§ no medication formulary to ensure that there were clear and transparent 
criteria for adopting, removing or updating the medicines in use in the 
hospital,   
§ a relative lack of current policies, protocols, and guidelines to support relevant 
clinical staff in safe prescribing and administration of medications at ward 
level, 
§ a Drugs and Therapeutics Committee that had only met once within the 
previous year and one which had only re-convened two days preceding 
HIQA’s inspection. 
Of the nine hospitals that needed to strengthen governance, inspectors found 
moderate issues of concern relating to medication safety and governance in five of 
these hospitals which included the following: 
§ Drugs and Therapeutics Committees which were not operating according to 
their terms of reference, and governance arrangements which needed to be 
strengthened and developed to progress improvements in relation to 
medication safety. 
§ the frequency of Drugs and Therapeutics Committee meetings was not in line 
with their terms of reference. 
§ a lack of clarity regarding who was responsible for medication safety.   
§ a Drugs and Therapeutics Committee that was primarily focused on financial 
management rather than patient safety. 
§ a lack of oversight of medication safety incidents by a hospital’s Drugs and 
Therapeutics Committee. 
Drugs and Therapeutics Committee scope and functions 
The terms of reference for Drugs and Therapeutics Committees should clearly define 
its role, functions and objectives to avoid ambiguity and clearly articulate its position 
and reporting structures within a hospital.17,33,34 
Positive findings from the monitoring programme highlighted that all Committees 
had terms of reference, with a small number in draft format. These terms of 
reference outlined the objectives, membership, frequency of meetings and reporting 
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relationships. However, inspectors found a lack of consistency in the scope, role and 
function of terms of reference in different hospitals, even between similar types of 
hospitals. For example, medication safety, clinical trials or formulary oversight was 
not included on all hospital’s terms of reference. 
While the functions of many Drugs and Therapeutics Committees have not 
necessarily changed in recent years, the scope has expanded from the approval of 
medications towards ensuring patient safety and promoting evidence-based practice. 
HIQA found that Drugs and Therapeutics Committee terms of reference in the 
hospitals inspected had numerous different functions including: 
§ formulary management, 
§ ensuring rational use of medications, including antimicrobials, 
§ dealing with product shortages,  
§ policies and procedures regarding medication use,  
§ quality assurance activities, 
§ audit and evaluation, 
§ risk management, 
§ oversight of nurse prescribing.  
There was poor compliance with the functions and objectives outlined in the terms 
of reference in many hospitals, for example: 
§ frequency of meetings and attendance was not in keeping with terms of 
reference, 
§ medication incidents were not reported to the Committee as outlined in the 
terms of reference, 
§ audit reports were not formally submitted to the Drugs and Therapeutics 
Committees for review,  
§ management of hospital formulary was not as described in terms of 
reference. 
HIQA found that very few hospitals inspected (with some exceptions) had measured 
the effectiveness of their Drugs and Therapeutics Committees in an objective way. 
Only four Committees had produced a Drugs and Therapeutics Committees annual 
report on the Committee’s activities. 
HIQA concluded that these findings highlighted variance in the scope, role and 
function of Drugs and Therapeutics Committees across Irish hospitals. In the 
absence of national guidance on terms of reference for these committees, hospitals 
should refer to international evidence to guide the role, function and scope of Drugs 
and Therapeutics Committees.33, 34 
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Chairperson and membership 
Previous HIQA publications have identified the requirement for integration of clinical 
and corporate governance structures in hospitals with clear accountability 
arrangements.37,38,39 Best practice recommends that Drugs and Therapeutics 
Committees are chaired by an individual with the necessary expertise, interest and 
time to devote to the position.  Membership should reflect the size of the hospital 
and services provided with representatives from all the major specialities; medical, 
nursing, pharmacy, hospital management and other relevant stakeholders including 
community partners.17 Membership may also include front-line clinical staff that 
experience operational issues with medication management. Strong commitment 
and regular attendance are essential requirements from all members. 
HIQA found that Drugs and Therapeutics Committees were chaired by a consultant 
physician with one exception which was chaired by the Hospital Manager. Drugs and 
Therapeutics Committees in the hospitals inspected were multidisciplinary to reflect 
the fact that medicines management was the responsibility of a number of clinical 
professional groupings and composition was generally representative and commonly 
included doctors, pharmacists, nurses, and representatives from hospital 
management and quality and risk departments.  
Many hospitals reported that regular attendance of members at the Drugs and 
Therapeutics Committee meetings was a requirement to remain on the committee, 
in line with its terms of reference. Despite this requirement, inspectors found that 
overall there was poor representation on the Drugs and Therapeutics Committee 
from surgeons, general practitioners (GPs) and community pharmacists. Inspectors 
were informed by some hospitals that while GP representation was difficult due to 
the timing of meetings, medicines-related issues were raised as required at separate 
GP liaison committee meetings or other similar forums.  
Medication safety strategy  
Hospitals should have a clear corporate strategy that sets out the organisation’s 
mission, values, role, functions and actions to be taken to meet organisational 
goals.40,41 A medication safety strategy should be aligned to the hospital’s strategic 
goals to send out a clear message from clinical leaders and management that 
medication safety is an important goal that all healthcare staff should strive to 
attain.  
A hospital’s medication safety strategy needs to clearly articulate the long-term 
strategic and short-term operational goals, be consistent with national and 
international standards and policy,40 and may include:  
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§ focusing on driving evidence-based practice and standardisation of medication 
management systems  
§ ensuring collaboration with multidisciplinary teams so that evidence-based 
practices are implemented through continuous quality improvement in 
medication management  
§ focusing on high-risk medicines, high-risk processes and medicines use 
systems, continuity of care, medication management workforce, evaluation 
and research. 
Inspectors found widespread variance in the planning and delivery of medication 
safety programmes. HIQA found that the majority of hospitals inspected lacked an 
up-to-date medication safety strategy, and associated operational plan, to guide the 
overall approach to medication safety.  
Six hospitals had a formal medication safety strategy in place guided by national and 
international guidance on strategic planning in medication safety.30,40,41, 42 One 
specialist maternity hospital had a detailed medication safety strategy developed 
following a multidisciplinary medication safety self-assessment carried out in 2015.43 
Fourteen hospitals had a documented medication safety programme or plan to guide 
the overall approach to medication safety. The remaining 14 hospitals inspected had 
no written plan for improving medication safety, but had some medication safety 
interventions in place.  
More established medication safety programmes, particularly in larger Dublin-based 
hospitals were generally managed by designated full-time or part-time medication 
safety officers, whereas in smaller hospitals this function was mostly managed by 
the Chief Pharmacist.  
HIQA concluded that while the majority of hospitals had a medication safety 
programme, the absence of formalised medication safety strategies, programmes or 
plans had resulted in a lack of direction within some hospitals in the collective 
approach to dealing with medication safety.  
Hospitals without formal medication safety strategies, programmes and plans could 
learn from the experience of hospitals with more advanced medication safety 
programmes. In doing so, hospitals can rapidly progress improvement by adopting 
research-based and proven approaches to medication safety in an Irish context.  
In the absence of national guidance in this area, international research40,41 that 
outlines best practice in relation to medication safety strategic planning and quality 
improvement should be used. 
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Formulary management 
Medications are one of the largest areas of potential risk as well as health 
expenditure, and hospitals must have explicit medication selection systems that are 
transparent and evidence-based to ensure safe and cost-effective prescribing.33  
For a Drugs and Therapeutics Committee to be effective, there must be a structured 
drug selection system that is explicit in its methodology, transparent and evidence-
based. A formulary†††includes the hospital’s locally approved medications which staff 
can use as a reference document to ensure safe and cost-effective prescribing. The 
purpose of maintaining a hospital formulary is to ensure that appropriate governance 
exists with the Drugs and Therapeutics Committee around what is approved for use 
and that in doing so, a proper safety evaluation occurs before medications are 
introduced into practice at the hospital.44 In addition, the Drugs and Therapeutics 
Committees should provide oversight in the selection of appropriate new medicines 
for addition to the formulary and promote safe, rational and cost-effective use of 
medications.  
A carefully considered formulary guides clinicians in choosing the safest, most 
effective medications for treating specific medical problems.  
HIQA found that 13 hospitals had developed and managed hospital formularies of 
medications over a number of years. Many of these hospitals had dedicated 
pharmacy resources allocated to formulary management outlined in Figure 3. 
                                       
†††  A formulary is a managed list of preferred medicines that have been approved by the hospital’s 
Drugs and Therapeutics Committee for use at the hospital. Use of a formulary ensures governance 
oversight of the introduction and ongoing use of medicines in practice at the hospital, and in doing so 
ensures an appropriate level of management control over medicines use, in the interest of both 
patient safety and financial management. 
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Figure 3: Number of hospitals inspected with a formulary of medications 
In contrast, 21 of the 34 hospitals inspected had no documented formulary, but had 
a pharmacy inventory stock list. Inspectors found that considerable variation existed 
in the interpretation of what constituted a hospital formulary. This was particularly 
evident in regional model 2 and 3 hospitals, as they had significantly less resources 
such as formulary pharmacists or formulary subcommittees in comparison to larger 
hospitals to develop a formulary.  
However, HIQA found that although resources were far more limited in smaller 
model 2 and 3 hospitals, two hospitals had overcome this challenge by sharing a 
formulary developed in a model 4 hospital. Collaboration and sharing of information, 
such as this, could enable wider establishment of medication formularies across all 
public acute hospitals and there is considerable potential to share the experience of 
those hospitals that have more advanced hospital formularies.  
A good example of formulary management from St Vincent’s University Hospital, 
Dublin and collaboration and sharing this with St Columcille’s Hospital’s Drugs and 
Therapeutics Committee is detailed below. 
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Formulary Management at St Vincent’s University Hospital, Dublin 
At St. Vincent’s University Hospital, the Drugs and Therapeutics Committee was 
responsible for administering an evidence-based formulary of medications accepted 
for use in the hospital. Decisions to add or remove medications from the formulary 
were guided by written criteria. New medicines were evaluated on the basis of 
efficacy, safety, quality and cost. Decisions with significant budgetary impact were 
additionally overseen by senior hospital management. Mechanisms were in place to 
communicate with healthcare professionals about all aspects of the formulary 
system. In addition, there was a process in place for an annual review of the 
formulary.  
The Pharmacy Department had established and maintained a medicines guide‡‡‡ 
containing the hospital medication formulary. The medicines guide was accessible 
via all computer desktops in the hospital and as an application which could be 
downloaded to mobile phones or tablets. This use of mobile technology gave 
prescribers easy access to the guidelines at the point of prescribing. 
St Columcille’s Hospital’s Drugs and Therapeutics Committee formally adopted the St 
Vincent’s University Hospital formulary and adapted it for use within the hospital. 
 
Hospitals should work to develop local formularies that are more than an inventory 
of medications stocked in the hospital. Inspectors were given examples of where, in 
the absence of established formularies, hospitals had taken steps to minimise 
unnecessary duplication of the same basic drug type, drug entity, or drug product. 
Optimising the number of medications and products available from the pharmacy 
can promote patient safety and produce financial benefits. It also minimises the 
number of medications with which practitioners must be familiar. 
Inspectors were informed by some hospitals that in the absence of a local formulary, 
the adult or children’s British National Formulary (BNF)§§§ was used in the hospital. 
However, this document is too comprehensive to substitute as a local formulary as it 
includes every medication licensed for use in the United Kingdom. A consequence of 
using the BNF in place of a local formulary is that staff prescribing and administering 
                                       
‡‡‡ Prescribers’ Guide: a guide that contains the agreed policies involving medications as well as the 
hospital medication formulary. 
§§§ British National Formulary :a reference book that contains authoritative information and advice on 
prescribing medicines including indications, contraindications, side effects, and recommended doses. 
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medications may not be familiar with the medications prescribed or the local policies 
governing the use of the medication.  
HIQA found that a formal application process for evaluating requests for new 
medications to be added to the hospital’s formulary, or for use in the hospital, had 
been introduced in 24 of the 34 hospitals inspected, but not all of these hospitals 
reported that error potential was included in the discussion and evaluation process. 
The quality of the formulary submissions were not reviewed in this monitoring 
programme. 
Recommendations  
1. Hospitals must have formalised governance structures with clear accountability 
and responsibility arrangements to support medication safety. This includes a 
functioning Drugs and Therapeutic Committee with clear terms of reference and 
membership to provide assurance that medication management systems are 
safe.  
2. The Drugs and Therapeutics Committee should have a clear strategic plan for 
improving medication safety outlining short, medium and long-term goals, with a 
supporting time bound medication safety programme or plan.  
3. Hospitals should have a defined formulary process to outline medicines that are 
approved for use in the hospital and provide information and standard guidance 
on the use of these medicines.  
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2.2 Medication safety support structures and processes 
Lines of enquiry: 
Ø Patient safety is enhanced through an effective medication safety programme 
underpinned by formalised governance structures and clear accountability 
arrangements. 
Ø Hospitals develop effective processes to promote medication safety that are 
implemented and supported by clear and up-to-date policies, procedures and 
or protocols. 
Clinical pharmacy services 
In the past, clinical pharmacy services were limited to the dispensing**** of 
medications. However, modern high-quality healthcare requires greater clinical 
involvement by clinical pharmacists in patient care to ensure the safe and effective 
use of medicines.5,45,46,47,48,49,50,57  Clinical pharmacy services are described as a team 
of pharmacists who, with the support of pharmacy technicians, are involved in the 
delivery of a combination of activities to individual patients.51  
The role of the clinical pharmacist can vary from a ward-based clinical pharmacy 
service to a team-based clinical pharmacy service. Ward-based clinical pharmacy 
activities include reviewing medication prescriptions to prevent prescribing-related 
incidents, providing a counselling service to patients in relation to their medicines 
(particularly high-risk medications), providing advice, education and training to staff 
to support safe medication management, performing medication reconciliation, 
participating in audit, conducting research, and implementing quality improvement 
initiatives in relation to medication management.51 
A more comprehensive team-based model of clinical pharmacy service performs the 
duties as detailed above, but also provides a collaborative approach to service 
delivery. This means clinical pharmacists are deployed to clinical teams rather than 
wards, and may have certain direct intervention powers agreed with medical 
consultants.52  
International and national studies have highlighted that hospitals face challenges in 
providing clinical pharmacy services due to insufficient resources.6,52,53,54,55,56,57  A 
United Kingdom report titled ‘operation productivity and performance’ in 2016 55 
identified significant variation in total pharmacy and medicines cost across acute 
                                       
******** Dispensing: involves the preparation, packaging, labelling, record keeping, and transfer of a 
prescription medication to a patient or an intermediary (such as a nurse or doctor), who is 
responsible for administration of the medication. 
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healthcare trusts†††† (or regions), while allowing for some variation due to trusts 
providing teaching or specialist services.55 This report found that over 55% of 
pharmacy staff time was spent on infrastructure services like buying and supplying 
medicines. The report recommends that more than 80% of trusts’ pharmacist 
resources should be utilised for direct medicines optimisation activities,‡‡‡‡ medicines 
governance and safety remits, while at the same time reviewing the provision of 
local infrastructure services, which could be delivered collaboratively. Medicines 
optimisation is critical for patient safety and to reduce overall medicine costs. 
Therefore, deploying more clinical pharmacists to work closer with patients, doctors 
and nursing staff is required to deliver the best possible use of medicines. 
A 2016 report produced by the Pharmaceutical Society of Ireland highlighted 
significant variation in the level of clinical pharmacist review of patients in hospitals, 
especially in many smaller hospitals.57 A HIQA report on the review of antimicrobial 
stewardship in public acute hospitals in Ireland in 2016 also found considerable 
variation among the levels of clinical pharmacists engaging in ward-based clinical 
work; most clinical pharmacy posts were located in the major Dublin hospitals and 
staffing of clinical pharmacy roles was least resourced in model 3 hospitals, 
particularly in rural areas.53  
There is currently no national strategy or standards outlining the requirements for 
providing clinical pharmacy services in Irish hospitals, as recommended by a report 
on the review of hospital pharmacy services in Ireland in 2011.6 The lack of national 
clinical pharmacy standards creates variability in how pharmacy services are 
delivered and resourced.6,56,57,58  
The Society of Hospital Pharmacists in Australia (SHPA) developed standards in 2016 
for the practice of clinical pharmacy services to include maximising clinical 
pharmacist services activities and managing workload.51 The European Association of 
Hospital Pharmacists (EAHP) published commonly agreed statements on what every 
European health system should aim for in the delivery of hospital pharmacy services. 
The EAHP plan to work with national member states to fully implement these 
statements.59 In Ireland, these agreed statements could form the basis for the 
development of national clinical pharmacy standards. In addition, the Pharmaceutical 
Society of Ireland’s 2016 report made 24 recommendations to support the future of 
pharmacy practice in Ireland.57 These recommendations could also support the 
development of standards in clinical pharmacy services in Ireland.52,57 
                                       
†††† A National Health Service trust is an organisation within the English NHS generally serving either 
a geographical area or a specialised function (such as an ambulance service). In any particular 
location there may be several trusts involved in the different aspects of healthcare for a resident. 
‡‡‡‡ Medicines optimisation: a person-centred approach to safe and effective use of medications, to 
ensure people obtain the best possible outcomes from their medications.  
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Clinical pharmacy service provision 
Pharmacy leaders and hospital managers are responsible for ensuring that 
pharmacists provide the best care within a given budget and use their resources 
effectively.60 HIQA found that medication programmes were actively progressed 
throughout the hospitals as a result of initiative and leadership from chief 
pharmacists in collaboration with multidisciplinary teams and with support from 
senior management.61 This was found particularly in large Dublin hospitals, but also 
in some regional hospitals.  
Consistent with HIQA findings on the antimicrobial stewardship programme in 
2015,53 inspectors found that there was a very uneven distribution of clinical 
pharmacy staff resources across public acute hospitals. Almost half of the clinical 
pharmacist resources were located in Dublin model 4 hospitals and staffing levels 
were more inadequately spread in model 3 and model 2 hospitals, particularly those 
in non-urban settings.  
In the 34 public acute hospitals inspected in year one of this programme, HIQA 
found that 25 hospitals had provided a ward-based clinical pharmacy service to the 
inpatient ward areas; however this service was limited in some hospitals to medical 
wards only. Three hospitals provided a team-based model of clinical pharmacy with 
the aim of better interdisciplinary collaboration with patient care.  
The pharmacy service in five of the 34 hospitals inspected was almost entirely 
involved in the dispensing of medications in the pharmacy department with one 
hospital supported by a clinical pharmacy service from a nearby local hospital. This 
meant that these five hospitals had either no or limited clinical pharmacy service 
available for review of patient’s medications in clinical areas. Therefore, they could 
not sufficiently support the implementation of an effective medication safety strategy 
and medication plan.  
In addition, activities by clinical pharmacists that support medication safety were 
inadequate due to the relative lack of clinical pharmacy management and resources. 
These activities included: reviewing medication prescriptions to prevent medication 
prescribing-related incidents, involvement in tracking and trending of medication 
incidents, medication reconciliation, participating in audit and implementing quality 
improvement initiatives in relation to medication management.  
HIQA found that of the seven model 4 hospitals inspected, six hospitals provided a 
ward-based clinical pharmacy service to all inpatient ward areas with the exception 
of one or two ward areas. Four specialist hospitals provided a ward-based clinical 
pharmacy service. One of the seven model 4 hospitals inspected provided a team-
based pharmacy service where clinical pharmacists were deployed to a number of 
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medical teams rather than wards, and had certain direct intervention powers agreed 
with consultants as detailed below. 
 
Team-based Collaborative Pharmaceutical Care in Tallaght Hospital model 
(PACT) 
Configuration of the clinical pharmacy service at Tallaght Hospital was changed from 
a ward base model to a team-based Collaborative Pharmaceutical Care in Tallaght 
Hospital model (PACT) following a study in 2014 to improve care and reduce the rate 
of serious adverse medication events.52  
This model which has as a first step been prioritised towards adult medical and 
vascular surgical patients on the basis of risk facilitates medication reconciliation by 
clinical pharmacists and physicians at admission, during inpatient care and at 
discharge. The hospital planned to expand this service to inpatient services by the 
end of 2018.   
 
HIQA found that two model 3 hospitals had also adopted a team-based approach 
and provided a team-based model of clinical pharmacy service throughout the 
hospital. However, in contrast to model 4 and specialist hospitals, almost all of the 
model 3 hospitals inspected had not provided a pharmacy service provision to all of 
the wards due to a lack of clinical pharmacy resources. HIQA found that: 
§ nine model 3 hospitals had provided a ward-based clinical pharmacy service 
to a limited number of inpatient ward areas 
§ one model 3 hospital’s pharmacy service was mostly involved with   
dispensing of medicines, this meant that the clinical pharmacy service 
available to the ward was very limited.  
Similarly, HIQA found that in the seven model 2 hospitals inspected, three had a 
clinical pharmacy service in most ward areas and four had a pharmacy service that 
was almost entirely dispensing. One hospital, that had no clinical pharmacist on site, 
was instead supported by a clinical pharmacy service from a nearby model 3 local 
hospital (see Figure 4).  
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Figure 4: Clinical pharmacy provision in hospitals inspected 
Paediatric intensive care units and neonatal units in large teaching hospitals had a 
clinical pharmacy service. In contrast, HIQA found that in most regional paediatric 
and maternity units, within a public acute  hospital, there was limited access to a 
clinical pharmacist. Paediatric and maternity services were generally offered a 
reactive clinical pharmacy service. This meant that a clinical pharmacist would 
respond to medication-related queries and incidents only on request. HIQA was 
informed that while management in these hospitals were aware of this risk, they 
reported that limited clinical pharmacy resources meant that other adult clinical 
areas, where high-risk medicines were administered, were prioritised over paediatric 
and maternity services.  
The limited and incomplete clinical pharmacy cover in paediatric and maternity 
services including paediatric and special care baby units in a number of the regional 
public acute hospitals areas was of concern to HIQA. International evidence on 
medication errors indicates that a small error in dose of medication given to children 
has a greater risk of harm compared with in the adult population.62 Furthermore, 
paediatric prescribing requires weight-related dose adjustment and other dose 
calculations, which are less common in adult prescribing. Published studies also 
indicate babies in the special care baby units are more likely to experience a 
medication error than other hospitalised patients and to experience more harm when 
a medication error does occur.63,64  
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HIQA found much progress had been made by committed front-line pharmacy staff 
in advancing medication safety. However, there was major variation in clinical 
pharmacy resources from hospital to hospital. HIQA found evidence that a number 
of hospitals were better resourced with clinical pharmacists in comparison to others 
and, in general, larger voluntary hospitals had prioritised resourcing of clinical 
pharmacy services more than smaller statutory hospitals. 
Medication reconciliation 
Medication reconciliation is a process of creating and maintaining the most accurate 
list possible of all medications a person is taking including drug name, dosage, 
frequency and route. This process identifies any discrepancies and ensures any 
changes are documented and communicated to complete an accurate medication 
list.65 There are three steps in the medication reconciliation process:  
1. Collecting: This involves the collection of the medication history and other 
relevant information.  
2. Checking: This is the process of ensuring that the medicines, doses, 
frequency and routes, etc. that are prescribed for a patient or service user are 
correct.  
3. Communicating: This is the final step in the process where any changes 
that have been made to a patient or service user’s prescription are 
documented, dated and communicated to the person to whom the patient’s 
or service user’s care is being transferred.65, 66,67  
Medication reconciliation should be carried out in a structured manner by trained 
and competent health professionals with the necessary knowledge, skills and 
expertise.65,68,69 Therefore, using a multidisciplinary approach that involves nurses, 
pharmacists, doctors and other appropriately trained healthcare professionals from 
acute, ambulatory and community services is essential to drive and sustain 
medication reconciliation.70 Equally, defining how patients, families or caregivers 
should be involved in the whole process of knowing and maintaining an up-to-date 
real time medicines list is imperative.70  
International studies support the implementation of medication reconciliation as an 
effective strategy to lower rates of medication errors throughout patients’ hospital 
stays and subsequently across transition to community care or other care 
facilities.3,68,70,71,72,73 In addition, published studies indicate that children in paediatric 
hospitals are more likely to experience a medication error than other hospitalised 
patients and the implementation of medication reconciliation systems have the 
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potential to reduce non-intercepted medications errors on admission or unintentional 
changes to repeat prescribed medication.74,75 
A number of studies completed in Ireland support the implementation of medication 
reconciliation.52, 65, 76 One study, in a large Irish teaching hospital where medication 
reconciliation had been completed by clinical pharmacists, showed that medication 
errors were identified in approximately one in four patients’ admission 
prescriptions.52  A second study relating to the medication details documented on 
discharge found that a lack of reconciliation on discharge from public acute hospitals 
in Ireland was frequent and can contribute to patient harm or unplanned 
readmission.76  
In 2008, the Report of the Commission on Patient Safety and Quality Assurance in 
Ireland identified that, as a key part of their safety and quality governance 
framework, hospitals must prioritise the implementation of formal medication 
reconciliation. This report identified that hospitals should include regular audits and 
the deployment of resources for this purpose.23  
However, studies have also highlighted the barriers to implementing medication 
reconciliation for hospitals70,71,76, including the following: 
§ the difficulty patients have in accurately recording their medications  
§ polypharmacy§§§§  
§ multimorbidityl  
§ pharmacy staff time and work constraints  
§ a lack of resources, most notably clinical pharmacy staff to perform 
medication reconciliation.  
A number of studies confirmed that the clinical pharmacist contributed positively to 
medication reconciliation on admission.45,46,47,48,49,50 However, as medication 
reconciliation is a labour-intensive process, the high cost of clinician time 
(pharmacists, doctors, nurses) spent sourcing patients’ real-time medicines list 
cannot be ignored. It is essential for hospitals to identify situations most likely to 
benefit from medication reconciliation, such as patients on high-risk medications, 
and determine the most appropriate and efficient way to do this.70,71,72,77,78 The use 
of pharmacy technicians could also be a useful strategy for developing and 
expanding medication reconciliation with appropriate supervision and education.79,80  
While multidisciplinary collaboration can improve medication reconciliation, the 
reconciliation process without technological aids remains costly and time-consuming 
                                       
¡ Polypharmacy: the concurrent use of multiple medications by a patient. 
l Multimorbidity: commonly defined as the presence of two or more chronic medical conditions in an 
individual. 
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for healthcare providers.76,81 Medication reconciliation supported by information 
technology has been shown to minimise medication-related incidents.70  
Medication reconciliation practice and the required discussion among healthcare 
professions and hospitals to reduce medication errors on admission and discharge 
are not widely standardised.77,82 Key to implementing medication reconciliation is 
establishing who should be ultimately accountable for obtaining the patients’ 
medication information, and performing the various steps in the reconciliation 
process. Studies indicate that while different professional groups such as doctors, 
pharmacists and nurses recognise the importance of medication reconciliation, there 
remains a lack of clarity regarding the roles and responsibilities for medication 
reconciliation. Therefore, policies and training are required to provider clarity for 
roles and responsibilities when medication reconciliation is introduced to a 
healthcare setting.77,82 
Through the medication monitoring programme HIQA found that there were various 
systems implemented to support medication reconciliation. While some hospitals had 
more comprehensive systems in place, other hospitals had a significant amount of 
work to do in implementing medication reconciliation.  
HIQA found that where there was leadership from chief pharmacists, supported by a 
functional Drugs and Therapeutics Committee and Hospital Management, medication 
reconciliation was more likely to be implemented and pharmacy-led.  
Of the 34 hospitals inspected:  
§ Three hospitals were completing medication reconciliation on admission and 
discharge. These hospitals had a policy, audit and training in relation to 
medication reconciliation. 
§ Thirteen hospitals were completing medication reconciliation on admission in 
most of the clinical areas of the hospital, through a process that was 
pharmacy-led.  
§ Fourteen hospitals had implemented aspects of medication reconciliation on 
admission in a small number of wards with limited clinical pharmacy resources 
supported by multidisciplinary teams. 
§ Four hospitals reported to inspectors that patients’ medications were checked 
by nurses and or doctors on admission.   
In the 29 hospitals inspected that had an Emergency Department, eight had 
implemented medication reconciliation for admitted patients in their Emergency 
Department.  
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Of the 34 hospitals inspected, HIQA found that eleven hospitals had supported 
medication reconciliation with the implementation of a policy. Seventeen hospitals had 
completed audits. Six hospitals had provided training on medication reconciliation. 
Ten hospitals used an electronic system to support medication reconciliation (this will 
be discussed in more detail in the next section).  
HIQA found that a number of hospitals had implemented areas of good practice with 
medication reconciliation. An example at Naas General Hospital is detailed below. 
 
Medication reconciliation at Naas General Hospital 
Naas General Hospital’s medication reconciliation service was underpinned by a 
policy which specified that all patients should have medication reconciliation 
completed within 24 hours of admission, or on the next working day. A clinical 
pharmacist collected a gold standard pre-admission medication list using a 
designated admission medication reconciliation form.  
Patients’ pre-admission medications were verified by a clinical pharmacist using two 
information sources, one of which was always the patient or their carer, and these 
were then compared to the patient’s hospital medication prescription chart.  
This hospital had evaluated its medication reconciliation service in line with the 
World Health Organization’s guidelines for medication reconciliation. A series of 
audits conducted in 2009, 2011 and 2016 in this hospital indicated that medication 
reconciliation practices had, over this timeframe, significantly decreased the number 
of unintentional unresolved medication discrepancies at 48 hours.  
 
Technology and medication safety 
eHealth is defined by the World Health Organization as the adoption of information 
and communication technologies in delivering health services.83 Regardless of 
worldwide advances in the use of health information technology, the implementation 
of electronic prescribing is delayed in many countries.84,85,86 A study relating to e-
medication in European countries identified that the implementation of nationwide e-
medication systems and cross-border harmonisation was slow due to the 
development of privacy and security requirements.87  
Internationally, the US government and the European Commission have made 
progress with the requirement for healthcare to move from one that was primarily 
paper based to one that uses electronic technology.88,89, 90The government policy in 
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the UK has also driven the use of technology in healthcare with a plan for the 
National Health Service (NHS) to be paperless by 2020 91,92 and Scotland is regarded 
to be well advanced with adopting eHealth by that date.93  
In Ireland, HIQA completed a review of ePrescribing and electronic transfer of 
prescriptions in 2012.94 This review identified that six jurisdictions***** throughout 
the world had commenced or had already implemented ePrescribing solutions 
focusing mainly on the prescribing and dispensing of medication in the community. 
This international review provided information and evidence to aid the development 
of an electronic transfer prescription solution for Ireland. Likewise, the Department 
of Health in Ireland has developed an eHealth strategy (2013) to provide a roadmap 
on eHealth with proposals for governance and delivery structures.85  
Numerous international and national studies support the introduction of ePrescribing 
to improve inpatient medicines management systems and reduce medication 
errors.73,74,87 While these studies highlight that there are patient safety benefits to 
introducing ePrescribing, these benefits are dependent on successful implementation 
of the system, as various unintended consequences relating to the introduction of 
ePrescribing have also being identified in the literature. For example, new 
medication errors can occur when a prescriber picks from a drop down menu drug 
list, or while filling in free text fields electronically, or as a consequence of overriding 
medication alerts.95,96 Despite these findings, the widespread use of ePrescribing 
offers opportunities to improve patient safety with regard to medication use. These 
opportunities include access to shared medication-related information by healthcare 
professionals including clinical information at the point of care.84 In addition, the 
benefits of ePrescribing also relate to generating legible and complete medication 
orders and sharing this information with multiple professionals within the hospital 
and the wider community.97  
A number of technologies have being developed to reduce medication errors and to 
support ePrescribing.84 These technologies include the following: 
§ pharmacy-based systems to manage stock control 
§ clinical speciality-based systems including cancer and intensive care systems  
§ components of large hospital information systems such as electronic health 
record 
§ hospital software systems developed locally by hospital informatics teams. 
 
                                       
***** The six jurisdictions: New Zealand, Australia, the Netherlands, England, Scotland and Northern 
Ireland. 
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The Department of Health’s 2013 eHealth strategy aims to deliver a more 
personalised patient-centred healthcare system to reduce errors. This involves the 
integration of all information involved in the delivery of healthcare through 
information technology-based systems.85 Potential priority projects that fall under 
the eHealth strategy include: 
§ Electronic Health Record (EHR) 
§ National health identifier infrastructure 
§ ePrescribing systems 
§ Telehealthcare††††† – relating to chronic diseases 
§ development of Patient Summary Records 
§ online access to Health Information 
§ National Patient Portal.‡‡‡‡‡ 
A national Electronic Health Record (EHR) has been identified by the Health Service 
Executive (HSE), national directors and clinical leaders as a key requirement for the 
future delivery of healthcare.98 The EHR is the cornerstone of the eHealth Strategy 
as it supports the creation and sharing of key patient information. Key to 
implementing the EHR is the need for an Individual Health Identifier§§§§§ on which 
the electronic health record system is centred.98 The national EHR will consist of core 
operational functions including ePrescribing.  
The national technology project for 2018, as part of the eHealth strategy, will initially 
focus on the shared care and discharge summary data from the Maternity Newborn 
Clinical Management system.99 
ePrescribing aims to reduce errors due to manual prescribing. The eHealth strategy 
describes ePrescribing as the transmission of prescription or prescription-related 
information between prescriber, dispenser, pharmacy, and health plan using 
electronic media through an ePrescribing network.85 
During this monitoring programme HIQA found that a number of hospitals had 
implemented quality improvement initiatives using technology to assist. These 
included ePrescribing, smart pump technology, technology-assisted medication 
reconciliation, standardised concentration infusions and innovative uses of smart 
phone technology.  
                                       
††††† Telehealth: involves the distribution of health-related services and information via electronic 
information and telecommunication technologies. 
‡‡‡‡‡ A National Patient Portal: allows the patient to view their medical data, submit statements of 
intention, appoint representative(s), and act on behalf of the persons. 
§§§§§ An Individual Health Identifier (IHI): a number that safely identifies a person using a health or 
social care service. This number will be used to safely identify the individual and link their health 
records from different health systems to generate a complete medical history.  
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Four hospitals reported that they had implemented some elements of electronic 
prescribing in critical care areas, and eight hospitals had implemented electronic 
discharge summaries to support medication reconciliation and communication with 
community pharmacists and GPs.  
An example of electronic prescribing demonstrated to inspectors during an 
inspection is detailed below.  
 
Electronic prescribing and medicines administration record at St. James’ 
Hospital, Dublin 
St James’ Hospital had commenced work in early 2017 on a project to introduce an 
electronic prescribing and medicines administration record (ePMA)ⱷ. One of the 
deliverables of this project was that electronic prescribing would be launched in 
clinical areas in April or May 2018. Access to such information could potentially 
support prescribers in better decision-making, prescribing and improve patient 
safety. This project is considered a positive step in progressing medication safety in 
a hospital setting.  
Inspectors viewed this system, which had been established in an outpatient area for 
a number of years, and observed that this computerised decision support system 
provided integration of patient clinical history, clinical review, laboratory results, 
diagnostics and medication history.  
 
Smart pump technology 
Another use of technology to support medication safety is ‘smart-pump’ technology 
which is computerised infusion devices with multiple safety features that include 
customised drug libraries and drug calculations.100,101 The benefits of using 
technology can provide high-level risk-reduction strategies, including forcing 
functions****** and constraints, automation†††††† and standardisation (Appendix 7). 
                                       
****** Forcing functions: are design processes so errors are virtually impossible to make, for example 
removal of a product from use such as concentrated potassium in ward areas. 
†††††† Automation:  the method of making a machine, a process, or a system work without being 
directly controlled by a person. 
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HIQA found during the medication monitoring programme that three specialised 
hospitals had implemented smart pump technology‡‡‡‡‡‡ with customised drug 
libraries. Two of these three hospitals had collaborated on the development of a 
customised drug library for smart pumps and shared access to drug libraries with 
other regional paediatric units in public acute hospitals. This was a good example of 
effective collaboration, facilitating wide-scale standardisation of medication practices, 
sharing expertise and experience with efficient use of resources. One paediatric 
hospital that implemented a drug library for use with smart pump technology was 
Our Lady’s Children’s Hospital, Crumlin as detailed below.  
 
Smart pump technology at Our Lady’s Children’s Hospital, Crumlin 
Critically ill, paediatric patients are at high risk of medication error. Our Lady’s 
Children’s Hospital had enhanced medication safety in this vulnerable cohort of 
patients through the introduction of smart pump technology and the development of 
a drug library containing an agreed list of standardised concentration infusions.  
A cross-site collaborative multidisciplinary working group was convened and the 
hospital’s drug library was further developed to enable its use across the Irish 
Paediatric Acute Transport Service and in the paediatric intensive care unit at the 
Temple Street Children’s University Hospital.  
Standardisation was achieved for paediatric patients requiring intensive care 
management with continuous intravenous infusions. The safety benefits of this 
cross-site standardisation of the smart pump infusion drug library containing a list of 
standardised drug concentrations facilitated a reduction in the risk of medication 
error when critically ill children were transferred from one facility to another. 
 
Medication reconciliation on discharge using information 
technology   
Medication reconciliation supported by an electronic tool has been shown to 
minimise medication incidents.94,102 In addition, working with community pharmacists 
and GPs to support medication reconciliation is essential to reduce the risk of 
medication incidents occurring.70  
                                       
‡‡‡‡‡‡ Smart pump technology: computerised infusion devices with multiple safety features 
that include customised drug libraries, dose calculations based on programmed patient weights and 
the setting of dose limits. 
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The use of handwritten discharge summaries and prescriptions remains routine 
practice in the majority of Irish hospitals.76 This ongoing practice is more likely to 
result in one or more medication errors than if this system was computerised.81 
Therefore, the process of electronic reconciliation of medication records between 
hospitals, GPs and community pharmacists would ensure an accurate, up-to-date 
electronic medication list, common to all healthcare providers.70,81  
Three hospitals inspected used technology to assist with medication reconciliation. 
One of these hospitals had implemented a specific system to support medication 
reconciliation and reported that over 80% of patients had an electronic discharge 
prescription completed on discharge that had been reconciled with their pre-
admission medication list. This was then transmitted to the patient’s GP via 
Healthlink.§§§§§§ 
Similarly, two other hospitals were involved in trialling a pharmacy-led discharge 
medication reconciliation as described below. 
 
Naas General Hospital and St Luke’s General Hospital, Kilkenny: 
Medication reconciliation using technology 
Naas General Hospital and St Luke’s General Hospital, Kilkenny collaborated on a 
joint initiative using medication computer software in collaboration with e-Health 
Ireland, the School of Pharmacy at University College Cork, and an industry sponsor.  
This was described as a computer software programme used by pharmacists to 
generate a record of medication reconciliation on admission and to generate a 
discharge prescription.  
Discharge prescriptions were then printed and signed by the patient’s doctor and 
sent to the patient’s GP, community pharmacy and nursing homes where applicable.  
An evaluation of this initiative found it improved efficiency and patient safety. 
 
                                       
§§§§§§ Healthlink: provides a web-based messaging service which allows the secure transmission of 
clinical patient information between hospitals, healthcare agencies and GPs. 
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Other uses of electronic technology 
HIQA found other examples of electronic technology systems which were 
implemented to support medication safety. These included: 
§ computer technology, tablet and applications at point of care to support drug 
prescribing and administration 
§ drug libraries with standardised medication infusion concentrations in 
intensive care units 
§ standardised protocols and dosing regimens, for example insulin and 
chemotherapy 
§ piloting the use of mobile technology to record medication incidents 
§ ePrescribing in a small number of critical care units. 
Four of the 34 hospitals reported to inspectors that they had implemented 
automated dispensing systems in some areas.≠ Inspectors observed an automated 
dispensing system in one hospital’s pharmacy department which had been recently 
introduced. Inspectors were informed that this was a positive addition to the 
dispensary, helping to increase efficiencies of the service and improve tracking or 
monitoring of medication stock levels. However, electronic ordering was not directly 
linked to the automated system at the time of this inspection.  
One hospital had implemented an electronic medication prescribing, compounding 
and administration system used in the oncology/ haematology service to support 
cancer treatment planning, therapy monitoring and the preparation of cytotoxic 
medications. This system was designed to minimise errors in intravenous medication 
preparation and administration, through bar code verification of prescribed 
medications, in this complex speciality.  
Three specialist maternity hospitals inspected were in the process of implementing 
an electronic healthcare record. This was part of a national Maternal and Newborn 
Clinical Management System99 which will include functionality and allow clinicians by 
the bedside to have each patient’s current and complete list of medications. 
Inspectors were informed that this project was being implemented nationally in 
maternity units on a phased basis.  
Utilising automation and intelligent systems has the potential to improve dispensing 
and prescribing medication management systems, support the effective use of 
clinical pharmacist resources and free up pharmacy resources to enable clinical 
pharmacists and other staff to provide an increased patient focused service.57  
                                       
≠ An automated dispensing system: a system controlled by a computer that stores, dispenses and 
tracks medications with the aim of improving efficiency and patient safety. 
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Recommendations 
1. A national plan for the development of comprehensive clinical pharmacy services 
that sets out the desired model of care, and the appropriate resources to ensure 
consistency across hospitals should be developed. 
2. Develop a national approach to advance medication reconciliation to include 
defining responsibility for medication reconciliation and using electronic solutions 
to reduce time spent by clinical staff on medication reconciliation. 
3. Utilise information technologies such as ePrescribing, smart pump technology and 
decision support tools to reduce medication incidents and risks. At a national 
level hospital groups should work together to commence the implementation of 
electronic solutions to improve medication safety. 
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2.3 Person-centred care 
Lines of enquiry:  
Ø Patients and or carers are informed about the benefits and associated risks of 
prescribed medicines in a way that is accessible and understandable. 
Patients should be supported to take responsibility, where possible, for maintaining 
and improving their own health through the provision of clear and relevant 
information in an accessible format.12 One in five patients has an adverse event after 
discharge from hospital, with the majority of these relating to medicines.103 Patient 
‘transitions’******* such as discharge from hospital to home is a complex process 
which should include patient education.104,105 Patients should be informed about any 
new medication they are prescribed or any changes to their medicines; this is 
especially relevant for patients who are taking multiple or high-risk 
medicines.106,107,108   
Appropriate education and the provision of written information to patients or carers 
is the responsibility of the multidisciplinary team that supports patients to make 
informed choices about their medicines and to achieve best outcomes with 
treatment plans.17,106 When patients are better informed about their medicines, 
compliance with taking medicines improves, and medication errors and visits to GPs 
and hospitals reduces.109,110 A well-informed patient and or family is less likely to 
make medication errors at home and can help prevent hospital staff from making 
medication errors.110  
All hospitals inspected reported that they had systems in place to support the 
provision of patient information and education in relation to medication use. 
However, the process for giving patients information and education about their 
medicines varied between hospitals from informal education to more structured 
education provided by an appropriate clinician and supported by individualised 
written information. 
HIQA survey  
Hospitalisation and subsequent discharge can involve multiple changes in medication 
regimes. Good communication between healthcare professionals and patients is 
needed to involve patients in decisions about their health and medicines.106 As part 
                                       
******* Transition of care: the movement of a patient from one setting of care to another. Settings of 
care may include hospitals, primary care, long-term care facilities, home health, and rehabilitation 
facilities. Transitions increase the risk of error due to the potential for miscommunication. 
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of the HIQA inspections, a small sample of recently discharged hospital patients 
attending the outpatient department were asked to complete an anonymised 
questionnaire in relation to prescribed medications. The questionnaire was designed 
to ascertain whether patients received appropriate information in relation to the 
purpose of, side effects of and instructions for taking their medicines. Three 
questions were asked with four or five possible responses (as outlined in Figure 5, 6 
and 7 below). The questions were: 
1. While in hospital did a member of staff explain the purpose of new medicines 
in a way you could understand? (Figure 5) 
2. Prior to discharge from hospital, did a member of staff tell you about the 
possible side effects of medicine to watch for when you went home? (Figure 
6) 
3. Were you told how to take your newly prescribed medicines in a way you 
could understand? (Figure 7) 
A total of 444 patients who had been inpatients in hospitals within the past six 
months, and who were prescribed regular medications, completed the questionnaire.  
Over half (58%) of patients reported that a member of staff explained newly 
prescribed medicines in a way they could completely understand. An additional 16% 
reported that new medicines were explained to some extent. One in 10 patients 
reported that the purpose of their new medication was not explained.  
 
 
Figure 5: Question 1. While in hospital, did a member of staff explain the purpose of new medicines 
prescribed in a way you could understand? 
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One in four (25%) patients reported that they were not told about possible side 
effects, 17% stated they were told to some extent, and 43% reported they were 
given complete information as detailed in Figure 6 below. 
 
Figure 6: Question 2. Prior to discharge from hospital, did a member of staff tell you 
about possible side effects of medicine to watch for when you went home? 
 
Over six out of 10 patients were told how to take their medicines in a way they could 
understand. Nearly one in ten were told ‘to some extent’ and 11% were not told 
how to take their medicines in a way that they could understand. 
 
Figure 7: Question 3. Were you told how to take your newly prescribed medicines in a 
way you could understand? 
 
It is acknowledged that the sample size of patients who completed the anonymised 
questionnaire was small and therefore was not representative of all recently 
discharged patients taking prescribed medications from each hospital. However, this 
patient questionnaire did provide some baseline information about outpatients’ 
understanding of medications in the hospitals inspected. 
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The results found during this monitoring programme broadly reflected findings from 
the recent National Patient Experience Survey†††††††111 which are outlined below.       
It must be noted that the questions differed slightly as the focus for this phase of 
the medication safety monitoring programme was on new medicines, whereas the 
questions in the National Patient Experience Survey asked about all medicines a 
patient was taking.  
 
Figure 8: Results of the National Patient Experience Survey medication-related questions 
(12,940 responses to these questions) 
                                       
††††††† The National Patient Experience Survey: was a nationwide survey which asked people for 
feedback about their stay in hospital. The survey was a partnership between the Health Service 
Executive (HSE), HIQA and the Department of Health. All adult patients discharged during May 2017 
who spent 24 hours or more in a public acute hospital, and have a postal address in the Republic of 
Ireland were asked to complete the survey. 
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These results highlight a significant requirement to improve the information given to 
patients at a national level in relation to the purpose and side effects of medicines. 
Patient information and education in relation to medicines 
A number of hospitals, particularly specialist and paediatric hospitals demonstrated 
good examples of formalised patient information and education processes in place, 
provided by staff such as pharmacists, clinical nurse specialists or midwife 
specialists.  
Other hospitals inspected outlined a multidisciplinary team approach to patient 
information and education in relation to medication use with doctors, nurses and 
pharmacists providing patient information and education. The multidisciplinary 
approach described to inspectors was in some cases informal, and was dependant 
on the expertise and time available for staff to provide patient education. 
Appropriate policies, procedures, protocols and guidelines should be in place to 
support patient education and to define each team member’s role and 
responsibilities in relation to providing medicines information for patients.112    
Clinical pharmacists were available to counsel patients in relation to medication 
issues on request from a patient, nurse or doctor in most hospitals inspected.  
Most hospitals informed inspectors that clinical nurse and midwife specialists 
provided education and support to patients on medication management, most often 
in relation to medicines for diabetes, respiratory conditions, cardiac failure and after 
having a stroke.   
Patient information leaflets were available at the point of care in many hospitals. 
However, the quality and quantity of the patient information leaflets available varied 
across hospitals. Information leaflets on oral anticoagulants were the most 
commonly available information leaflets. Patients in one hospital were provided with 
an anticoagulant alert card which they could show to their healthcare provider to 
alert them to the fact that they were taking oral anticoagulation medication. 
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A number of hospitals had introduced quality improvement initiatives to improve 
patients’ knowledge of their medicines as detailed below. 
 
 
Quality improvement initiatives to improve patients’ knowledge 
of their medicines 
Cappagh National Orthopaedic hospital  
Clinical pharmacists offered counselling to all patients in the orthopaedic ward on 
newly prescribed oral anticoagulant. Clinical pharmacist also provided counselling on 
medications to patients in the acute rehabilitation unit and provided a medication 
planner for patients and or carers, prior to planned discharge.  
 
Coombe Women & Infants University Hospital 
The Coombe Women & Infants University hospital identified that parents of babies 
discharged on complex medications required additional education and support and 
were provided with this support by neonatal nurses, pharmacists and the discharge 
nurse. The pharmacist often linked with external community pharmacists or external 
hospitals to ensure a continuous supply of medications for the baby follow transfer 
or discharge.  
Education for parents was undertaken throughout the hospital stay to prepare the 
parents and the baby for discharge. In addition, the hospital held monthly support 
groups for parents of these babies post discharge, to provide an additional source of 
support and educational opportunity if required.  
 
Know your medication initiatives 
Campaigns were in progress in the National Maternity Hospital, Tallaght Hospital and 
Mayo University Hospital with the aim of increasing patient awareness of their 
medications, through the use of medication leaflets that were carried by patients 
that included a record of their medicines. 
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Quality improvement initiatives to improve patients’ knowledge 
of their medicines 
Patient education on anticoagulant medications:  
Oral anticoagulants‡‡‡‡‡‡‡ and more recently direct oral anticoagulants§§§§§§§ 
(DOAC) have been widely identified as high-risk medications which continue to be a 
key medication safety priority in many hospitals inspected.  
To reduce this risk, clinical pharmacy counselling can be provided to patients who 
are commenced on anticoagulant medication. In other hospitals where clinical 
pharmacy were only assigned to certain ward areas, patients were provided with 
anticoagulation counselling on their assigned wards and in other areas of the 
hospital if requested by nurses or doctors.  
For example, Tallaght Hospital had set up an atrial fibrillation clinic with the support 
of the pharmacy service to manage atrial fibrillation and supervise the use of direct 
oral anticoagulants (DOACs).  
Naas Hospital pharmacy departments had also established outpatient education 
clinics for patients who had commenced on direct oral anticoagulant medication. 
This was an example of how hospitals optimised their available clinical pharmacy 
resources to provide standardised care to patients prescribed high-risk medications. 
 
 
Giving patients the opportunity to provide feedback about medicines information 
they receive provides hospitals with the opportunity to implement improvements 
where deficiencies are identified.107  
Some hospitals sought patients’ opinions and used the information to improve care; 
such as in St James’ Hospital as detailed in the following table. 
  
                                       
‡‡‡‡‡‡‡ Anticoagulants: are commonly referred to as blood thinners that prevent or treat blood clots, 
but these medicines also carry an increased risk of bleeding or clots, so patient education and regular 
monitoring of blood levels are essential to maintain patient safety and ensure good patient outcomes.    
§§§§§§§ Direct oral anticoagulants: are medications used to treat or prevent blood clots. However, 
there is a potential for bleeding with their use or clotting leading to stroke with missed doses. Options 
for anticoagulation have been expanded recently with the introduction of new anticoagulants called 
direct oral anticoagulants. 
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St James’ Hospital medication safety focus groups  
While developing a medication strategy, St James’ Hospital identified that the views 
and experiences of patients and their carers on medication safety issues should form 
an essential component of the medication strategy. A patient safety focus group was 
held in March 2016 with the hospital’s Patient Representative Group which was 
formed at the beginning of 2016. Three themes emerged relating to medication 
management from the focus group and action plans to address these issues were 
incorporated into the hospital’s medication strategy. The themes identified were:  
§ patient control over self administration of their own medication 
§ communication between patients and healthcare professionals on medication 
issues 
§ unsecured medications left by patient bedside following medication 
administration. 
Hospitals must develop strategies to ensure patient engagement in relation to the 
safe use of medicines so that patients receive appropriate, individualised information 
in relation to their medicines, in particular with new medicines and high-risk 
medicines. 
Recommendation  
1. Hospitals should build patient education requirements into the medication 
management process, based on services provided and their patient population, to 
ensure patients and or care givers are given the appropriate medicines-related 
information.  
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2.4 Policies, procedures, protocols and guidelines and 
information to support medication safety 
Lines of enquiry: 
Ø Hospitals develop effective processes for medication management that are 
implemented and supported by clear and up-to-date policies, procedures 
protocols and guidelines. 
Ø Essential information supporting the safe use of medicines is readily available 
in a user friendly format and is adhered to when prescribing, dispensing and 
administering medications. 
The National Standards outline that healthcare should be delivered according to 
policies, procedures, protocols and guidelines based on national and international 
research to achieve best outcomes for patients.12 Clinical policies, procedures, 
protocols and guidelines based on best available evidence reduce variation in 
practice, improve patient outcomes and ensure the efficient use of healthcare 
resources.113,114     
Medications have proven to be very beneficial in treating illness and preventing 
disease, but advances in medication have also resulted in added complexity and 
potential risk for patients.1 Therefore, organisations need policies, procedures, 
protocols and guidelines, used in conjunction with higher level risk-reduction 
strategies to effectively guide medication safety and reduce risk.115  
It is important that policies, procedure, protocols and guidelines are developed using 
a standardised approach, involve end-users, are easy-to-read and officially 
introduced with training and wide distribution to front-line staff.17 ,116 Oversight of 
medication policies, procedures, protocols and guidelines should include the 
expertise of the hospital’s medication safety governance group, such as the Drugs 
and Therapeutics Committee, to ensure they are appropriately developed, 
implemented and have effective assurance mechanisms in place to monitor their 
effectiveness.17  
Policies, procedures, protocols and guidelines must be readily available at the point 
of use******** to ensure the information is followed in practice.17 In addition, clinical 
staff should have access to medicines information resources at the point of 
prescribing and preparation, and should have access to clinical expertise such as 
clinical pharmacists. 
                                       
******** Point of use: includes when prescribing, preparing or administering medicines.   
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Types of policies, procedures, protocols and guidelines could include, but are not 
limited to: guidelines for healthcare staff on safe procurement, dispensing, storing, 
compounding, prescribing, administration and monitoring the effects of medicines.17 
Additional policies, procedure, protocols and guidelines to support safe medication 
management system may also include:  
§ criteria for inclusion of medicines on the hospital medicines formulary    
§ medication reconciliation  
§ high-risk medicines  
§ generic substitution   
§ provision of medicines information on discharge  
§ related guidance to support the medicines management system such as: 
- patient identification  
- use of abbreviations 
- reporting of incidents and adverse drug reactions.17  
Policies, procedures, protocols and guidelines should be controlled documents using 
appropriate systems.17,116 This process involves defining controls needed to develop, 
approve, review, identify changes and revision status, and provide access at point of 
use.  
On inspection HIQA found that most hospitals had medication management policies, 
procedures, protocols and guidelines in place. The majority of hospitals inspected 
had procedures in place for the approval of these documents, most of which were 
up to date and document controlled. Hospitals had processes in place for 
communicating new policies, procedures, protocols and guidelines to staff, but 
limited evidence of auditing compliance with these was found.    
The majority of hospitals reported that the hospital’s Drugs and Therapeutics 
Committee approved policies, procedures, protocols and guidelines to support safe 
medication management systems. In a small minority of hospitals, medication-
related policies, procedures, protocols and guidelines were reviewed by the Drugs 
and Therapeutics Committee before final sign off by other committees (such as the 
Clinical Governance Committees) or senior hospital management.  
The majority of hospitals inspected had an electronic document control system which 
supported the document control process and provided staff access to the most 
current version of the documents at point of use. These systems also sent email 
alerts to identified personnel when the documents were due for review. The 
hospitals which did not have electronic document control systems stored their 
documents on hospital computer systems where staff could access them, but 
document control depended on manual systems.   
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Although some hospitals were challenged with keeping documents up to date, 
almost all hospitals’ documents viewed by inspectors were version controlled with 
review dates clearly stated.          
Inspectors found that some hospitals had externally developed policies, procedures, 
protocols and guidelines and or medicines information sources which were not 
reviewed and or not approved for use within the organisation. This could result in 
staff accessing information which is not appropriate to the local setting.  
Inspectors found some good examples of sharing of policies, procedures, protocols 
and guidelines and collaboration within hospital groups with efficient use of staff 
expertise and resources.  
Access to medicines information and decision support tools  
Access to relevant up-to-date and accurate medicines reference information and 
decision support tools†††††††† is essential at all stages of the medication management 
pathway.17  A range of medicines information and decision support tools were 
available to guide staff involved in providing safe and effective medication 
management within the clinical areas of all hospitals inspected. However, the 
quantity and quality of the tools available varied between hospitals.  
The clinical pharmacist was identified by staff as a key source of medicines 
information in clinical areas inspected. Computerised decision support tools, 
including electronic tablet devices and smartphone applications, in place in some 
hospitals, had provided easy access to accurate, up-to-date information at the point 
of prescribing, preparation and administration of medicines. Given the diversity of 
medical applications available to support decision-making and future technology 
developments, quality control of all information sources to guide staff is vital, and 
should be under the governance of the Drugs and Therapeutics Committee.117 
Intravenous medication monographs 
In the majority of hospitals inspected, locally developed or adapted intravenous 
medication monographs‡‡‡‡‡‡‡‡ were available to provide staff with a quick reference 
guide to support the safe and effective prescribing and administration of intravenous 
                                       
†††††††† Decision support tools: are resources that provide guidance or incorporate knowledge to help 
clinicians make the most appropriate clinical decision for patient care.  
‡‡‡‡‡‡‡‡ Intravenous medication monographs: an approved set of standardised and approved 
instructions for the correct preparation and administration of intravenous medication, that have been 
designed to reduce the risk of error, and that are specifically tailored to the intravenous medicines 
stocked within the hospital.  
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medications. The intravenous medication monographs observed were in bound, hard 
copy versions which could only be updated in totality or in unbound hard copy 
versions where individual monographs could be updated as required and in 
electronic format.  
However, a number of hospitals did not have appropriate information in place. One 
hospital had intravenous medication monographs specifically designed for use in 
another hospital, and two other hospitals had commercially available intravenous 
medication guidance which had not been formally reviewed as suitable for the 
hospitals. Inspectors identified this as a risk, as instructions for administration of 
intravenous medications could be inappropriate for use in that particular clinical area 
or hospital with potential for patient harm. For example, medications designed for 
use in a critical care area being administered in a general ward area.  
Other hospitals that did not have intravenous medication monographs used 
instruction leaflets from manufacturers as a reference guide for staff. This could 
pose a risk if a medicine is used in the wrong way or in the wrong setting. Although 
manufacturers’ information is up to date and accurate, it cannot ensure that 
medicines are being used in an appropriate setting. For example using procedural 
sedation in general ward areas§§§§§§§§ which carries additional risk if these agents are 
used without the requisite patient monitoring.118  
Intravenous medication monographs were available in electronic format at the point 
of medication preparation in three of the hospitals inspected. The use of technology 
to deliver resources at the point of care can enhance clinical practice, provide work 
practice efficiencies and improve safety of medicines use by increasing guideline 
update and adherence.17  However, in embracing technology for medicines 
information resources hospitals need to ensure that the required information is still 
accessible to staff at point of use, such as, the clinical room where medications are 
prepared.  
An example of intravenous medication monographs in electronic format at the point 
of medication preparation is described in the following example. 
 
 
 
                                       
§§§§§§§§ Procedural sedation: a technique of administering sedatives or dissociative agents with or 
without analgesics to induce a state that allows the patient to tolerate unpleasant procedures while 
maintaining cardiac and respiratory function.  
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Tablet devices in clinical rooms at Our Lady’s Children’s Hospital Crumlin  
Our Lady’s Children’s Hospital Crumlin had electronic tablet devices in clinical rooms 
which contained an electronic version of up-to-date intravenous monographs, the 
hospital formulary and medication safety alerts. This information was standardised 
across the hospital, updated and controlled by the pharmacy department and 
approved though the Drugs and Therapeutics Committee.  
The use of electronic tablet devices was supported by an up-to-date standard 
operating procedure. A survey of front-line staff carried out after implementation 
found that their experience in using the electronic tablets had been positive with 
100% of staff using the tablet as the main means of checking medication 
information.  
 
Antimicrobial prescriber’s guidance 
Antimicrobial prescribers’ guidance was available to guide prescribers in all hospitals 
inspected. The antimicrobial prescriber’s guidance had been developed by some 
hospitals and shared with other hospitals within the hospital groups. For example, 
Galway University Hospital had developed an antimicrobial prescribing guideline, 
which was also available in mobile application format for smartphone devices. These 
guidelines had been shared and formally adopted by a number of hospitals within 
the Saolta Hospital Group.  Also five hospitals in the south east had collaborated in 
the development of a Guide for Empiric Use of Antibiotics which reduced variance in 
prescribing practice and provided prescribers in each organisation with evidence-
based, up-to-date information at the point of prescribing.  
The antimicrobial prescriber’s guidance was available to staff as a smartphone 
application in 19 of 34 hospitals, providing prescribers with up-to-date guidance at 
the point of prescribing.  
Prescriber’s guide  
Seven model 4 and specialist hospitals that were inspected had developed 
comprehensive medicine prescriber’s guides which were available in book and 
electronic format or as an application which could be downloaded. These guides also 
contained the hospital’s antimicrobial guidelines. Again, HIQA found good examples 
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of sharing between hospitals, for example, national maternity and paediatric 
hospitals shared their guidance with regional maternity and paediatrics units.    
Medicines reference information and decision support tools 
A number of medicines reference information and decision support tools were 
available to staff in hospitals inspected and are included in Figure 9. 
 
Figure 9: Medication information sources 
Advice and support from the clinical pharmacy service 
The nursing and medical staff in most of the hospitals inspected cited the clinical 
pharmacist as a key source of medicines information. In addition, six pharmacy 
departments from model 4 and specialist hospitals had a formal medicine 
information service********* with ready access for all staff to expert advice in the 
management of medication-related queries. For example one Hospital that provided 
this service reported over 1,300 enquiries answered from staff on medication 
annually.  
                                       
********* Medicines information service: Pharmacists give over the phone information and advice 
regarding all aspects of medicine use to doctors, nurses, pharmacists and other appropriate 
healthcare professionals. 
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Medicines information services support medication safety by providing accurate, up-
to-date, unbiased information on medication use. This information was provided to 
healthcare professionals for specific patient care or for general information on the 
safe use of medicines.  
Access to laboratory results to support safe use of medications 
Healthcare staff required access to complete and accurate patient information, 
relevant to the safe use of medications, at the point of clinical decision-making to 
ensure patient safety.17 All hospitals inspected reported that staff could electronically 
access laboratory results in all clinical areas. This was verified by inspectors on 
clinical areas visited during inspections.  
Informing staff of the hospital’s medicines management 
supports     
Relevant staff should be informed of policies, procedures, protocols and guidelines, 
medicines reference information and decision support tools developed, adapted or 
adopted by the Drugs and Therapeutics Committees.33  
HIQA found that medicines management information was provided to staff using a 
variety of methods such as: 
§ education sessions,  
§ meetings,  
§ safety huddles,†††††††††  
§ emails,  
§ safety alerts,  
§ pharmacy department memos, 
§ and medications safety bulletins.  
One hospital held a medication safety week at which they launched their medication 
management policy. Two hospitals developed a ‘one minute’ slide outlining 
medicines information on a slide presentation, which staff could read in one minute. 
This ‘one minute’ slide was circulated to staff via email, a group text message and 
the hospitals’ internal communication system.  
                                       
††††††††† Safety huddles are brief and routine meetings for sharing information about potential or 
existing safety problems facing patients or workers. They aim to increase safety awareness among 
front-line staff, allow for teams to develop action plans to address identified safety issues, and foster 
a culture of safety. 
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Sharing and collaboration of medicines information      
Inspectors observed some good examples of collaboration and sharing of policies, 
procedures, protocols and guidelines between hospitals in eight model 4 and 
specialist hospitals to reduce variation and improve outcomes and efficiency. One 
hospital shared their prescriber’s guide with two other hospitals within their hospital 
group. This was a good example of collaboration through the sharing of expertise 
and avoiding duplication of effort to support medication safety.  
Recommendations  
1. Hospitals should provide clinical staff with easily accessible information and or 
policies, procedures, guidelines and or protocols to guide the safe use of 
medicines at the point of prescribing, preparation and administration.  
 
  
Medication safety monitoring programme overview report 
___________________________________________________________ 
Health Information and Quality Authority 
 
64 
 
2.5 Risk management and incident reporting 
Lines of enquiry 
Ø There are arrangements in place to identify report and manage risk related to 
medication safety throughout the hospital. 
The National Standards require that hospitals protect patients from the risk of harm 
associated with the design and delivery of healthcare. All hospitals should have 
effective and comprehensive processes in place to identify, understand, monitor and 
address risks associated with the use of medicines.12  
Effective prevention of medication incidents is dependent on:  
§ a well-organised incident reporting system  
§ a culture of openness with reporting and awareness among staff of the 
systemic nature of many of these errors  
§ analysing, tracking and trending medication incidents to identify emerging 
medication safety concerns 
§ an open disclosure process where hospital staff communicate with patients in 
an open and honest manner when things go wrong.119  
Measuring medication safety is a challenge and efforts to date have focused on 
voluntary reporting systems. Voluntary reporting systems are reactive by nature in 
that they analyse information after an incident‡‡‡‡‡‡‡‡‡ or near miss has occurred. 
There can be significant underreporting where staff do not, or are hesitant to report 
an incident.120 Medication incident reporting systems should operate in a ‘just 
culture’,§§§§§§§§§ be confidential, independent, timely and systems-oriented. 
 
 
                                       
‡‡‡‡‡‡‡‡‡ Medication Incident: any preventable event that may cause or lead to inappropriate 
medication use or patient harm while the medication is in the control of the healthcare professional, 
patient, or consumer. Medication incidents may be related to professional practice, drug products, 
procedures, and systems, and include prescribing, order communication, product labelling/ 
packaging/ nomenclature, compounding, dispensing, distribution, administration, education, 
monitoring, and use. 
§§§§§§§§§ Just culture: an environment which seeks to balance the need to learn from mistakes and the 
need to take disciplinary action.  
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Studies have found a positive association between increased incident reporting rates 
and a patient safety culture.5,10 This means that increased incident reporting is a 
good indicator of a positive patient safety culture within a hospital.10 In contrast, low 
numbers of incidents reported does not necessarily mean a low number of incidents 
occurring.  
Proactive risk assessments identify and systematically analyse risks and hazards 
embedded in a process to prevent an adverse incident or harm from actually 
reaching a patient. Proactive risk assessments can include: 
§ self-assessments against standards 
§ failure modes effects analysis**********  
§ chart reviews  
§ trigger tools††††††††††  
§ audit. 
A risk register is another way to proactively manage risk. The creation and 
maintenance of risk registers (at all levels within an organisation) ensures that risks 
relevant to a particular area of healthcare are identified and rated, and that 
appropriate controls and precautions are put in place to eliminate or reduce the 
risks. Where corrective actions are outside the control of the department or hospital, 
the risk is escalated through the appropriate governance structures.12,121  
In Ireland all public hospitals covered by the Clinical Indemnity Scheme have a 
statutory requirement to report all adverse clinical incidents and ‘near 
misses’‡‡‡‡‡‡‡‡‡‡ via the National Incident Management System (NIMS).§§§§§§§§§§ 
Adverse incidents involving medication*********** is one of the most common 
categories of adverse incidents in Ireland and internationally.2,4,16  
                                       
********** Failure Modes and Effects Analysis (FMEA): a systematic, proactive method for evaluating a 
process to identify where and how it might fail and to assess the relative impact of different failures, 
in order to identify the parts of the process that are most in need of change. 
†††††††††† Trigger tools: are ways of identifying and documenting patient harm using a systematic 
record review process on a randomly selected set of medical records using triggers as flags for 
patient harm. 
‡‡‡‡‡‡‡‡‡‡ A near-miss incident: an incident which could have resulted in harm, but did not either by 
chance or timely intervention.  
§§§§§§§§§§ National Incident Management System (NIMS): a risk management system that enables 
hospitals to report incidents in accordance with their statutory reporting obligation to the Clinical 
Indemnity Scheme (Section 11 of the National Treasury Management Agency (Amendment) Act, 
2000).   
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HIQA found that there was a disjointed approach to the oversight and management 
of medication-related incidents reported at some hospitals. All hospitals inspected 
had systems and protocols for reporting incidents, but the level of incidents reported 
in the majority of hospitals was not in line with internationally accepted norms and 
most hospitals were aware of the need for improvement.2 As a result of   
underreporting, key medication-related risks could not be understood, recorded, 
escalated or mitigated effectively by hospitals. 
Inspectors found that where hospitals had established medication safety 
programmes with strong leadership supporting a safer patient culture related to 
medication use, incident reporting rates had increased significantly in recent years. 
This reflected the emphasis placed on patient safety by clinical leaders, hospital 
management and, in particular, pharmacy departments in these hospitals. Increased 
incident reporting rates also reflect the willingness of front-line staff to provide 
information that ultimately could reduce the risk of harm to patients.  
In general, clinical staff reported medication incidents on a standardised form or on 
an electronic system which was sent to the hospital’s risk management department 
and entered onto the NIMS system. Although hospitals have a statutory 
requirement††††††††††† to report all adverse clinical incidents and near misses via the 
NIMS, inspectors found variations in what medication-related incidents were actually 
inputted into the NIMS. The time it took to complete an incident report form was 
identified by front-line staff as a key barrier to reporting medication incidents.  
In general, hospitals inspected had increased reporting rates of incidents in the last 
five years and Figure 10 illustrates the hospitals with the best reporting rates 
(hospital F was inspected in 2016 so no data was available for 2016 at this time). It 
should be noted that the hospitals detailed in the graph differ in size and services so 
comparisons cannot be made between them. Figure 10 serves to illustrate the 
improvement in the reporting of incidents. 
                                       
††††††††††† Under the National Treasury Management Agency (Amendment) Act 2000 there is a 
statutory requirement for all State authorities including the HSE and its funded agencies to report 
adverse incidents promptly to the Clinical Indemnity Scheme of the State Claims Agency (SCA) and to 
facilitate any subsequent investigation. This allows the SCA in conjunction with the HSE to identify 
and analyse developing trends and patterns, and to develop and implement risk mitigation strategies 
which is also important in the investigation of any subsequent claim.  
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Figure 10: Reporting rates of medication incidents reported in hospitals with established 
medication safety programmes over years 
In Hospital A, there was over 50 times more incidents reported in 2016 when 
compared with 2012. This reflected the emphasis placed on patient safety by the 
Pharmacy Department in particular, and the willingness of front-line staff to provide 
information that was ultimately intended to reduce the risks associated with 
medication use. However, a number of hospitals reported extremely low levels of 
medication incidents that were significantly below what would be expected (in the 
context of the likely presence of, on average, one medication incident per patient 
per day). For example, two smaller hospitals inspected reported three medication 
incidents over a period of 10 months, and another hospital reported four in total in 
2016. 
HIQA noted that despite the recent positive trend in reporting in some hospitals, the 
majority of reports were submitted by clinical pharmacists and nursing staff with 
limited evidence available to suggest that medical staff were reporting medication 
incidents. The culture of reporting medication incidents needs to be significantly 
improved to ensure that all healthcare staff feel safe to report incidents and near 
misses. Increased reporting will ensure safety surveillance is improved, learning is 
shared, and a safety culture is promoted and enhanced across the organisation. For 
example, one Hospital improved the culture of reporting medication incidents by 
providing feedback to each ward area and to medical and nursing staff with key 
points for learning and consideration. This information was stored in a ward folder 
for all staff to access. Following this initiative there was an improvement in 
medication incident reporting; with an increase from 25 to 60 per month reported by 
Hospital A Hospital B Hospital C Hospital D Hospital E Hospital F
2016 2339 1006 837 633 1035
2015 1931 790 861 562 1360 1165
2014 1337 615 948 765 1027 1124
2013 582 486 872 770 942 768
2012 45 400 859 866 925 577
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clinical pharmacists, nursing and some medical staff. Ward staff confirmed to 
inspectors that the regular feedback on medication incidents encouraged more 
reporting of incidents.  
Effective governance ensures the establishment of learning systems so that all 
experience within an organisation is shared and used to improve the system.122 
During the onsite inspections, hospital managers gave examples of how they 
provided feedback to front-line staff regarding lessons learned, for example via a 
staff newsletter.  
Staff in the majority of hospitals informed inspectors that they routinely received 
updates on medication errors that had occurred. However, inconsistencies were 
reported in the level and timeliness of feedback to staff once an incident had been 
reported.  
Feedback and learning methods should be improved to ensure that appropriate 
systems improvements are implemented as a result of these reports. Inspectors 
found limited evidence of sharing the learning from incidents and near misses across 
the hospital groups. 
Inspectors were informed that staff involved in a medication administration incident 
were required to complete additional training in five of the hospitals inspected. While 
HIQA acknowledges the importance of promoting a culture of professional 
responsibility it is important that following an incident or near miss a systems 
approach is used to identify causes of error. This ensures that systems are designed 
to reduce or eliminate errors and do not solely rely on staff vigilance.123,124  
Inspectors were informed that all hospitals had implemented the national open 
disclosure policy or had a local open disclosure policy in place to promptly inform 
patients when medication-related incidents occurred. Staff who spoke with 
inspectors were familiar with their hospital’s open disclosure policy. 
Analysis of medication incidents  
Hospitals should analyse or ‘track and trend’ medication incidents and near misses to 
identify trends and patterns so that action can be taken to prevent injury to patients 
and ensure that mistakes are not repeated.2  
All hospitals, with a small number of exceptions, categorised medication incidents in 
terms of patient harm, the impact of the incident for the patient and the likelihood of 
the risk reoccurring. The National Co-ordinating Council Medication Error Reporting 
and Prevention (NCC MERP) classification system was the most commonly used 
system (see Appendix 6). The index considered factors such as whether the error 
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reached the patient and, if the patient was harmed, to what degree. Other hospitals 
used NIMS and or the HSE Risk Assessment Tool and Risk Impact Table.125 One 
hospital used a locally developed tool to grade medication incidents; however this 
was not an evidence-based methodology for analysing patient safety incidents. 
The lack of standardisation in how medication incidents were graded and risk rated 
between hospitals in Ireland makes analysis and comparisons difficult. Due to this 
variation, data cannot be benchmarked between hospitals.  
HIQA found that sub-categorisation of medication incidents to aid analysis was 
evident in a number of hospitals and included; patient outcome, stage of the 
medication process‡‡‡‡‡‡‡‡‡‡‡, type of error and or therapeutic group or medicine. For 
example, one hospital had good tracking and trending of medication safety events 
including: 
§ overall trends 
§ location of events 
§ category of staff reporting events 
§ type of event 
§ severity grading of events 
§ types of medication errors causing patient harm. 
A number of hospitals with established systems for reporting and analysing 
medication incidents and near misses used analysed or trended data to identify 
emergent medication safety concerns and prioritise medication safety activities.126  
Direct acting oral anticoagulant medications featured frequently in reports from 
hospitals analysis of medication incidents. This highlights the importance of 
analysing and synthesising medication incidents reports in greater detail to reveal 
trends in incident reports. Such information is key to the implementation of proactive 
medication safety initiatives, and inspectors were shown examples of measures 
introduced by hospitals to address the risks identified in relation DOACS that 
included: 
§ Direct oral anticoagulant medications were not stocked at ward level and 
were supplied on a “named-patient basis” to the wards. High impact risk-
reduction strategies127 such as dispensing high-risk medicines on a named 
patient basis can catch and correct errors before they reach patients 
(Appendix 7).  
                                       
‡‡‡‡‡‡‡‡‡‡‡ Stage of the medication process: during dispensing, prescribing or administration.  
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§ Clinical pharmacists offered counselling to all patients newly prescribed oral 
anticoagulant medication  
§ The introduction of an anticoagulant sticker on the healthcare record to 
highlight anticoagulant use  
§ A dedicated medical intern lecture on prescribing of anti-coagulants was 
delivered as part of the intern education programme  
§ The publication of pharmacy newsletter to outline practice points with oral 
anticoagulant medications  
§ The distribution of a staff quiz which aimed to raise staff awareness of the 
risks associated with oral anticoagulant medications. 
Senior clinicians and pharmacists in Ireland East Hospital Group had collaborated to 
develop a direct oral anticoagulant therapy record. This booklet contained an 
anticoagulant therapy record and practical guidelines for the management of direct 
oral anticoagulant medications for both patients and healthcare professionals 
(written information has also been shown to augment patients’ knowledge about 
prescription drugs, even when oral communication does occur).  
Risk-reduction strategies 
Hospitals can develop risk-reduction strategies using the hierarchy of effectiveness 
framework to inform medication quality initiatives (Appendix 7). This framework127 
divides strategies in person or system-based and rates the level of risk-reduction 
strategies into: 
§ low leverage and least effective strategies  
§ medium leverage and moderately effective strategies 
§ high leverage and most effective strategies.  
Key elements that influence medication use such as the patient’s name, medicines 
information, labelling, packaging, drug standardisation and storage. These key 
elements can identify contributing factors that lead to medication errors and 
subsequently lead to the development of risk-reduction strategies. Inspectors found 
that all hospitals inspected had introduced some risk-reduction quality improvement 
initiatives to improve medication patient safety. The most common low level risk-
reduction strategies included policies and education.  
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Recognising that a small number of higher-leverage risk-reduction strategies were 
more effective to improve patient safety than a larger number of least effective 
strategies, inspectors found that 10 of the 34 hospitals inspected had implemented 
high level risk-reduction strategies.  
For example, as high-risk medications that bear a heightened risk of causing 
significant patient harm when not used correctly, many hospitals had implemented a 
number of high impact risk-reduction strategies to promote the safety of prescribing 
and administration of high-risk medicines. These included, but were not limited to 
the introduction of: 
§ standardised concentrations and dosing regimens for high-risk medicine 
infusions  
§ prescribing and administering restrictions 
§ reducing the number of strengths available for certain medications to reduce 
selection errors 
§ use of prefilled syringes in operating theatres where available 
§ availability of pre-mixed potassium available at ward level and the restriction 
of concentrated potassium to a limited number of identified areas in the 
hospital  
§ designated storage areas for high-risk medications in pharmacy and clinical 
areas. 
In addition, simple redundancies, such as removal of stocks of non essential high-
risk medications from patient care areas, had reduced the risk of serious incidents 
associated with these agents before they reached patients.  
High impact risk-reduction strategies such as dispensing high-risk medicines on a 
named patient basis can catch and correct errors before they reach patients. It was 
reported at interview that this had reduced the numbers of medication incidents 
associated with these agents. 
High-risk medications 
High-risk medication lists are maintained to determine which medications require 
special safeguards to reduce the risk of errors. The majority of hospitals maintained 
a list of high-risk medications at the time of the onsite inspection. A small number of 
hospitals had developed their own local list following an analysis of medication 
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incidents and near misses while other hospitals had adopted the Institute for Safe 
Medication Practices (ISMP) list of high-risk medications.128  
Inspectors found that of the 34 hospitals inspected, 31 had a list of high-risk 
medicines and three hospitals had neither a rationalised list of high-risk medications 
nor embedded processes to ensure that high-risk medications were stored, 
prescribed, dispensed and administered safely.  
Six hospitals used the acronym ‘A-PINCH’ which grouped medications into categories 
to facilitate education and to raise awareness of high-risk medications.129 The 
medications on the list included: 
Anticoagulants and anti-thrombotic medicines 
Potassium and intravenous Paracetamol  
Insulin’s and intrathecal or epidural administration  
Narcotics and neuromuscular blocking agents  
Cytotoxic medicines 
Hypertonic and hypotonic intravenous fluids. 
Hospitals promoted medication safety awareness of high-risk medications through 
posters displaying the list of high-risk medications.  
High-risk medications lists are ineffective unless risk-reduction strategies are in place 
and underpinned by policies, procedures and guidelines.127 Many hospitals had 
implemented a number of high impact risk-reduction strategies which reduced 
unwarranted variation and promoted the safety of prescribing and administration of 
high-risk medicines. However HIQA found that other hospitals relied solely on low-
leverage risk-reduction strategies to prevent errors, such as staff education and 
appeals for staff awareness.  
Hospital policies reviewed by HIQA relating to the use of high-risk medicines detailed 
a requirement for independent double-checks of high-risk medications. Independent 
double checks can be a useful mid-range strategy when applied correctly and used 
in combination with other error reduction strategies. However, it is important that 
this strategy is not assigned in isolation as a management strategy for all high-risk 
medications and result in an over reliance on staff vigilance to keep patients safe 
when receiving high-risk medications.  
Some hospitals put in place measures such as removal of stocks of non essential 
high-risk medications from patient care areas and or dispensing high-risk medicines 
on a named patient basis only.  
Medication safety monitoring programme overview report 
___________________________________________________________ 
  Health Information and Quality Authority 
 
73 
 
Other medication safety initiatives 
Medication safety has been identified by a number of bodies in Ireland as a key 
focus for improvement.23,24,25,26 ,27 International research highlights a number of 
successful strategies that have been implemented to reduce medication incidents 
29,127128 ,130 131 These strategies include having a standardised medication record, 
improved medicines distribution systems and technology, smart pump infusions for 
intravenous medicine administration, electronic medication management system for 
prescribing medicines and medication reconciliation.  
A Health Service Executive report entitled ‘safermeds’§§§§§§§§§§§ published in 2016 
identified areas for improvement with medication safety.132 HIQA found, during 
inspections, that a number of medicines quality improvement initiatives had been 
implemented consistent with recommendations relating to the ‘safermeds’ report 
2016.  
HIQA found that a little more than half of the hospitals inspected had medication 
safety quality improvement initiatives that were strategically driven by learning 
gained from analyses of medication incidents or near misses. Other hospitals had 
implemented some quality improvement initiatives to support medication safety 
although these were not strategically driven. 
HIQA found that medication quality improvement initiatives were sometimes 
implemented in response to a medication incident focusing on specific, circumscribed 
or restricted safety initiatives to manage the incident. HIQA recognise that this is a 
necessary and important endeavour. However, this approach is reactive in nature 
and it means that action is only taken after something goes wrong. Quality 
improvement with medication safety could be further enhanced with a strategic 
focus on targeted risk areas identified through other means, such as national or 
international trends. 29,127,130,131 A proactive strategic approach means that 
improvements with medication safety are implemented before an incident occurs 
and harms a patient. 
HIQA found that of the 34 hospitals inspected, 16 were significantly advanced in 
comparison to other hospitals in implementing medication safety quality 
improvement initiatives. A further 11 had implemented some quality improvement 
initiatives, and seven hospitals had only implemented one or two medication quality 
improvement initiatives.  
                                       
§§§§§§§§§§§ The National Medication Safety Programme, “Safermeds”, is one of the priority safety 
programmes within the HSE Quality Improvement Division. 
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In many hospitals with fewer quality improvement initiatives there was some 
correlation with resources. However, despite a lack of resources in other hospitals, 
HIQA found examples of quality improvements implemented due to considerable 
effort and leadership by individual clinicians and managers. Although commendable, 
medication safety initiatives that depend on individuals to implement and monitor 
progress are less sustainable in the long term. 
HIQA found that while 20 of the 34 hospitals inspected had implemented similar 
medication safety quality improvement initiatives within the previous two years as 
outlined in Figure 11 below, other hospitals were more advanced and used electronic 
technology to support medication safety. 
 
 
Figure 11. Medication safety quality improvement initiatives implemented by public acute 
hospitals. (Red apron************)  
                                       
************Red ‘do not disturb’ aprons: were worn by nurses to reduce interruptions during medicines 
administration as interruptions during medication administration rounds can contribute to medications 
errors.  
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One example used in the Rotunda Hospital is detailed below. 
 
Medication safety bundle, Rotunda Hospital 
The Rotunda Hospital had implemented a medication safety bundle containing multi-
faceted risk-reduction strategies to reduce the risks associated with the use of high-
risk continuous infusions in the Neonatal Intensive Care Unit (NICU).  
Risk-reduction strategies included an electronic dose calculator for high-risk 
continuous infusions, standard concentration intravenous infusions, electronic 
prescriptions and syringe labels for high-risk continuous infusions, and smart pump 
technology.  
The numbers of medication therapy issues which warranted intervention by the 
clinical pharmacist in the Neonatal Intensive Care Unit were measured before and 
after implementation of the medication safety bundle. Inspectors were informed that 
the implementation of the care bundle had resulted in a significant reduction in the 
number of clinical pharmacist interventions related to high-risk continuous infusions 
in the NICU. 
 
Improvements with medication prescribing records  
Common to all public acute hospitals inspected were prescribing errors identified 
through incident reporting, prescribing audits or nursing metric data. Hospitals 
responded with a revision of their medication prescription and administration record 
to reduce medication errors. For example, some adult medication prescription and 
administration charts were redesigned to include sections designated to 
antimicrobials, venous thromboembolism risk assessment and allergy status in 
response to medication incidents.133,134,135  
Overall, HIQA found that 20 of the 34 hospitals inspected had reviewed their local 
medication prescription and administration record to reduce procedural or clinical 
prescribing errors and inspectors found many examples of different designed 
medication prescription and administration records in hospitals inspected. Two 
paediatric hospitals had collaborated to develop a new medication prescription and 
administration record with features to reduce medication errors.  
Medication prescription and administration records were not standardised between 
hospitals or within hospital groups.  During the course of these inspections the HSE 
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published a National Medication Record Template for Adult Acute Care. These 
templates were intended to be used as an aid in the development or revision of local 
medication records, to incorporate good and safe practice but not be regarded as a 
definitive national standard. The HSE recommended that each hospital should take 
responsibility to ensure that its medication record is designed, tested, used and 
revised appropriately and safely.136  
Venous thromboembolism prophylaxis 
HIQA found that the majority of hospitals inspected reported that they had 
implemented the Health Service Executive’s (HSE) Quality Improvement Division 
initiative to improve venous thromboembolism†††††††††††† (VTE) prevention.133 This 
was a collaboration among multidisciplinary teams in Irish adult public acute and 
voluntary hospitals to achieve appropriate thromboprophylaxis‡‡‡‡‡‡‡‡‡‡‡‡ for their 
hospital’s inpatients, to reduce the risk of venous thromboembolism and to minimise 
harm and expenditure associated with unnecessary thromboprophylaxis.  
Improving medication safety practices in operating theatres 
A hospital’s operating theatre can be a high-risk area for medication errors.137,138, 139 
High risks with intravenous medications were identified in previous reports as part of 
HIQA’s prevention and control of healthcare-associated infection programme as 
outlined below: 
‘Scope to improve preparation, labelling and storage of intravenous 
medication in the clinical area was a re-occurring finding in 19 of the 32 
inspections. Inspectors found risks relating to the preparation of intravenous 
anaesthetic and emergency medicines and intravenous fluids in advance of 
giving these medicines to patients. These medicines had been stored 
inappropriately, left unattended and were not sufficiently and safely labelled. 
This was especially noticeable in operating theatres’.140 
HIQA found that a number of hospitals had implemented medication related quality 
improvement initiatives in operating theatres due to the high-risk nature of this area. 
This included the introduction of pre-filled labelled syringes in operating theatres to 
prevent the risk of patients getting the wrong medicine.  
                                       
†††††††††††† Venous thromboembolism (VTE): a blood clot consisting of deep veins thrombus (DVT) 
and pulmonary embolism (PE). Blood clots (thrombus) can form within deep veins (DVT) and these 
clots can fragment and travel to lungs leading to Pulmonary Embolism (PE). 
‡‡‡‡‡‡‡‡‡‡‡‡ Thromboprophylaxis: any preventive measure or medication that reduces the likelihood of 
the formation of blood clots. 
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Three hospitals had introduced standardised emergency trays systems in theatre to 
manage and prevent the risk of patients being inadvertently administered a 
potentially dangerous medication, such as an anaesthetic agent. For example, one 
hospital introduced two colour-coded trays to visually separate medication as a 
result of a medication incident. One coloured tray had medications for emergency 
use, and the second coloured tray was an individualised patient tray with 
medications specific to a patient’s requirements while in theatre.  
One Hospital had set up a Peri-Operative Medicines Committee which was a sub-
committee of their Drugs and Therapeutics Committee to introduce specific risk-
reduction strategies in the operating theatres. As a result the following 
improvements were introduced in the operating theatres:  
§ The stock list of drugs and equipment were standardised to support 
consistency in terms of medication stock and location and reduce 
interruptions to work flow during anaesthesia. 
§ Sound-a-likelook-alike drugs (SALADS§§§§§§§§§§§§) in the paediatric theatre 
were stored in different locations to reduce medications errors. 
§ The list of medications and equipment to deal with anaesthetic emergencies 
in infected cases using an ‘infected case anaesthetic emergency box’ were 
standardised. 
Recommendations  
1. At a national level, efforts to enhance learning from medication incidents and 
quality improvement initiatives should be put in place. This should include 
reviewing research in relation to medication safety, both nationally and 
internationally, to proactively address medication related risk. 
2. Centralised arrangements should be put in place to ensure good practices that 
HIQA has reported through these series of inspection are shared.  
3. Hospitals should support a culture of reporting medication related incidents and 
near misses among all healthcare professionals. Data from medication incidents 
should be routinely analysed to identify trends or patterns in relation to risk and 
identify areas that require targeted improvement.  
                                       
§§§§§§§§§§§§ SALADS: are ‘Sound-alike look-alike drugs’. The existence of similar drug names is one of 
the most common causes of medication error and is of concern worldwide. With tens of thousands of 
drugs currently on the market, the potential for error due to confusing drug names is significant. 
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2.6 Evaluation and audit of medication safety  
Line of enquiry:  
Ø The effectiveness of medication management systems are systematically 
monitored and evaluated to ensure they are effective.  
Hospitals should have arrangements in place to ensure the effectiveness of 
healthcare is systematically monitored and continuously improved. Review and 
evaluation of performance should use evidence-based information and metrics, 
focused on quality and safety outcomes for patients, using measures such as key 
performance indicators, audit and local, regional, national and international 
benchmarks. The information gathered should be used to improve services, and the 
learning gained should be shared throughout the hospital and, where relevant, with 
external organisations.12   
Good clinical governance************* processes support and ensure the effectiveness 
of medication management systems through monitoring, evaluation and audit.17 A 
governing committee, such as the Drugs and Therapeutics Committee, should be 
responsible for planning and oversight of the performance of medication systems 
and how the medication safety is monitored.17  
Evaluation of the use and safety of medicines should be planned in line with the 
hospital’s overall priorities and the medication safety strategic plan. Evaluation of 
medication safety should be formally planned, regularly reviewed and centrally 
coordinated to ensure that recommendations and improvements required are 
undertaken, with a lead person identified for the implementation of audit findings 
within specific timeframes.17 Areas for focus could also include areas of high risk or 
poor quality identified though a variety of sources such as complaints, incidents, 
adverse outcomes, or variation in clinical practice.17,141  Hospital managers and 
clinical leaders should ensure that recommendations are implemented to provide 
assurance that changes made result in improvement for medication safety.  
Learning from audit and evaluation of medication management systems should be 
shared locally via the most appropriate and effective mechanisms,142 so that the 
clinical workforce are informed of the areas that need improvement. Sharing findings 
also motivates staff to change practice and participate in improvement activities,17,141  
while contributing to a culture of transparency and accountability. Collaboration 
between internal hospital departments and external hospitals can also be beneficial 
                                       
************* Clinical governance is a system through which service providers are accountable for 
continually improving the quality of their clinical practice and safeguarding high standards of care by 
creating an environment in which excellence in clinical care will flourish. This includes mechanisms for 
monitoring clinical quality and safety through structured programmes, for example, clinical audit. 
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as the outcomes of a successful audit in one service may be transferable to other 
services.17,141  
HIQA found that elements of medication safety were evaluated and audited in the 
majority of hospitals inspected. However, monitoring of medication safety 
arrangements in many hospitals could be strengthened and formalised to provide 
assurances to senior management and clinician leaders. The establishment of a 
formal programme of evaluation and audit of medication safety could support this. 
One in three hospitals inspected had medication audit plans, presented mostly as a 
list of the medication audits which the hospital planned to undertake within a given 
period of time, usually a year. Compliance with these audit plans was demonstrated 
in some hospitals through a review of completed audits, but some hospital’s audit 
plans had only recently been developed.   
Two hospitals had audit plans that were aligned to a formalised medication safety 
strategy. All hospitals demonstrated evidence of medication safety audits completed 
for example, audits of:  
§ medicines reconciliation  
§ adherence to prescribing guidelines 
§ appropriate thromboprophylaxis in adult medical and surgical patients  
§ nurse prescribers’ medicinal product prescribing practices  
§ prescriber’s compliance with revised hospital prescription and administration 
record 
§ point prevalence survey of healthcare-associated infection and antimicrobial 
use  
§ compliance with prescribing guidelines in the care of the patients with 
diabetes 
§ medication fridges security, temperature and contents  
§ postnatal analgesia audits. 
HIQA found that only a small number of hospitals reported the results of audits to 
the governance group with responsibility for medication safety.  
A number of hospitals reported that audit planning was influenced by medication 
incident reports and trends. One hospital conducted an annual medication 
management systems review and this supported the development of the annual 
audit plan. In addition to an annual audit plan, hospitals reported that other audits 
were commissioned if a concern was identified that needed further evaluation of 
potential or actual risk to patients.  
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HIQA found that areas of good practice and areas for improvements were identified 
in most audits undertaken by hospitals. However, where audits identified areas for 
improvement, the monitoring of these recommendations was not consistent. HIQA 
found that time frames and the person responsible for medication safety quality 
improvement implementation was often not identified. HIQA observed evidence of 
re-audit occurring in some, but not all, hospitals inspected in order to provide 
assurance that the desired improvements have been made against the outlined 
standards.        
In addition, ownership of audits and responsibility for the management of audit 
findings and recommendations were identified as problematic in some hospitals. For 
example, this occurred when audits were initiated by doctors in training who moved 
regularly between hospitals and the recommendations in their audit reports were not 
handed over when they left.  
One hospital identified this and took steps to address this as outlined below.    
 
The Coombe Women & Infants University Hospital 
The Coombe Women & Infants University Hospital informed inspectors that all non-
consultant hospital doctors undertaking audits informed the Master of the hospital 
before commencing the audit.  
Each non-consultant hospital doctor’s audit was assigned a leader and or trainer, 
and in the event that the doctor left the hospital before that audit cycle was 
completed, the Master reallocated the audit to another non-consultant hospital 
doctor to ensure the audit cycle was completed and that learning was achieved by 
the hospital. 
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A few hospitals demonstrated good examples of medication safety quality 
improvement initiatives which were audited post implementation to ensure resultant 
improvement in practice occurred. An example of this is detailed in the box below. 
 
Lean medicine management project in Our Lady of Lourdes Hospital, 
Drogheda  
In 2016 the pharmacy department in this hospital had introduced a ‘lean medicine 
management project' on selected wards to enhance patient care by ensuring the 
correct medicines were available with minimum effort, reducing staff time being 
spent on stock control and releasing staff time for patient care.  
Following analysis of dispensing data, key interventions were introduced including 
revision of wards: medicines storage, medicines stock lists, top-up systems and 
ordering processes. The interventions resulted in significant improvement in 
efficiency with a 44% reduction in stock items being ordered, 40% reduction in 
nurses’ time being spent requesting stock items, a 38% reduction in pharmacy 
technician time being spent on medicine stock top up and 56% reduction in 
medicines required from pharmacy out of hours.  
Following the success of this project the pharmacy department planned to monitor 
and maintain progress on the current ward and extend the project hospital wide. 
 
Audits should be centralised to promote quality management of the audit process 
and shared learning.143 A number of hospitals reported that clinical audits were 
centrally coordinated, mostly by the clinical audit department, the quality 
department, or the medication safety officer. Two hospitals reported using the audit 
module within the hospital electronic document control system to support central 
coordination of audit and provide staff access to audit data.  
Hospitals outlined a variety of methods used to share audit findings with staff 
including department quality and safety meetings, journal club meetings, the 
intranet, newsletters and local conferences and seminars. A number of hospitals held 
clinical audit days providing an opportunity for multidisciplinary staff to present to 
hospital staff on audits undertaken. Grand rounds, education sessions and hospital 
meetings were also identified as opportunities to share audit results. A few hospitals 
reported that audit results were distributed to clinical staff in hard copy, or were 
available to staff on the hospital’s intranet or document management system.  
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Areas for improvement in the dissemination of audit results was identified by 
inspectors in a number of hospitals visited.   
Other processes used by hospitals for evaluating the quality of the medication 
management services included key performance indicators and nursing metrics.  
Nursing metrics 
Nursing and Midwifery Quality Care-Metrics are a process of performance quality 
indicators which provide a framework for how fundamental nursing care can be 
measured. Nursing metrics were monitored across almost all hospitals inspected. 
Most hospitals were using the HSE’s Nursing and Midwifery Quality Care Metrics,144 
while other hospitals had developed or adapted nursing metrics for local use. The 
majority of hospitals collected the metric data monthly, with frequencies of every 
two months and every quarter reported in other hospitals.  
Nursing and midwifery and paediatric quality care metrics included a review of 
practices around prescribing, storage, custody and administration of medicines. The 
results were available in clinical areas and displayed on notice boards visible to staff 
and members of the public in a number of hospitals. Areas for improvement in 
prescribing-related metrics were identified by inspectors in almost all hospitals 
visited.  
Key performance indicators 
Key performance indicators††††††††††††† were used by 28 hospitals to monitor 
performance and contribute to improvement. The number of key performance 
indicators measured varied between hospitals from measuring one indicator to 
measuring seven indicators. Key performance indicators are standards devised from 
evidence-based literature or consensus of experts to measure the quality of care, 
determine improvements required and positively impact care for patient.145 The key 
performance indicators measured were reported to the Drugs and Therapeutics 
Committee and senior management in most hospitals. Results were also reported to 
prescribers, but to a lesser extent.  
The Drugs, Therapeutics and Antimicrobial Stewardship Committee at the Royal 
Victoria Eye and Ear Hospital monitored medication safety using a number of key 
performance indicators as detailed below.  
                                       
††††††††††††† Key performance indicator: specific and measurable elements of practice that can be used 
to assess quality and safety of care. 
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Royal Victoria Eye and Ear Hospital: key performance indicators 
Medication safety was monitored and evaluated at the Royal Victoria Eye and Ear 
Hospital through a number of key performance indicators.  
Performance in relation to these key performance indicators was reported to 
prescribers, the Drugs and Therapeutics Committee and senior hospital 
management.  
There was evidence of review, revision and expansion of these key performance 
indicators by the Drugs, Therapeutics and Antimicrobial Stewardship Committee for 
2017 in documentation viewed by HIQA. 
 
The types of key performance indicators demonstrated in the hospitals inspected 
included:  
§ concentrated potassium chloride usage 
§ medication safety incidents reported  
§ medication safety incidents which resulted in patient harm 
§ clinical pharmacists intervention 
§ antimicrobial consumption 
§ chemotherapy extravasations  
§ medication reconciliation undertaken by clinical pharmacist within 24 hours of 
admission  
§ compliance with prescribing guidelines.   
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2.7 Training and education   
Line of enquiry: 
Ø Safe prescribing and drug administration practices are supported by 
mandatory and practical training on medication management for relevant 
staff. 
Research has shown that errors in healthcare are due to systems failures. For this 
reason, medication safety training and education should not primarily focus on 
making the individual healthcare worker more vigilant but should be delivered in 
conjunction with other risk-reduction strategies (Appendix 7). High-reliability 
organisations‡‡‡‡‡‡‡‡‡‡‡‡‡ use a systems approach to safety, and characteristics of 
these organisations include: well-trained personnel, teamwork, ongoing training, 
audits and continuous improvement initiatives.146 
The National Standards state that healthcare providers should recruit people with 
the required competencies to provide high-quality, safe and reliable healthcare. 
Those responsible for governance of healthcare organisations and hospitals should 
ensure that their workforce have these required competencies.12  
The World Health Organization has recognised the importance of educating 
healthcare professionals on the principles and concepts of patient safety. There must 
be a prioritisation of education, training and research in relation to patient safety 
(which encompasses medication safety) in both undergraduate and postgraduate 
education, but this must also be incorporated in a systematic way into ongoing and 
lifelong learning for clinicians and healthcare managers.147 Facilitating the 
development of collective knowledge, education, training and shared learning about 
unsafe practices is key to proactively supporting medication safety as individuals are 
rarely the single causes of errors.  
Healthcare providers should plan and devise training and education programmes for 
their workforce based on strategic objectives and the needs of their patient 
population. New staff should attend formal induction training programmes and all 
staff should be provided with the required ongoing education and training to 
maintain their competency, skill and knowledge.12 
                                       
‡‡‡‡‡‡‡‡‡‡‡‡‡ High-reliability organisations are those which consistently or reliably seek to balance both 
safety and effectiveness while operating in a high-risk environment. High-reliability organisations 
operate within complex environments with the potential for risk or error with serious consequences. 
They use technologies and processes to minimise these risks with well-trained staff who focus on 
continuous improvement within a good safety culture, adaptable to change. They have collective 
mindfulness where responsibility and accountability for reliability is distributed throughout the 
organisation. Such organisations aim to increase the quality of attention and alertness across all 
departments and teams.      
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Investment in ongoing education for healthcare professionals must be seen as a 
priority and supported at a senior and executive level as it is important to improve 
patients’ outcomes and is a pre-requisite to a high-quality, guideline-driven, 
evidence-based healthcare.148  
Education and training in relation to medication safety must be planned to ensure 
that staff can attend training, for example allocating time for frontline staff to attend 
in-house training. Some core characteristics of an effective medication safety 
training and education programme are listed below:17,43  
§ providing education on induction and on an ongoing basis to inform the 
workforce of safe procedures for prescribing, supplying, dispensing, storing, 
compounding, administration and monitoring of medications 
§ providing education to clinicians about new medicines and associated 
protocols, guidelines and restrictions for their use 
§ ensuring all staff receive patient-safety training that includes high-risk 
medications and associated risk-reduction strategies  
§ providing risk management education including incident reporting, learning 
from errors that occurred in the hospital and other facilities, and human 
factors that lead to errors  
§ evaluation of the competency of new staff and ensuring clinicians have the 
requisite training, especially before working in specialist areas, e.g. oncology 
or critical care 
§ ensuring staff have the necessary support and time to attend training, this 
includes those that provide education and training 
§ involving pharmacists in education on medication management processes. 
HIQA found that five hospitals had a comprehensive, ongoing medication safety 
training programme for staff. One hospital had an ongoing education programme for 
medication safety which was part of their overall strategy to increase awareness of 
the importance of medication safety. This programme was specific to medical 
consultants, non-consultant hospital doctors, nurses, clinical pharmacists and 
undergraduate students. 
All hospitals inspected had provided some training in relation to medication safety 
for clinical staff. However, considering the high risk related to the use of medications 
in hospital, inspectors found in general there was a lack of strategic planning in 
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relation to education and training in medication safety and a lack of formal, ongoing 
education programmes.  
Training conducted in relation to medication use and safety was usually limited to 
induction training for nurses and non-consultant hospital doctor’s. However, there 
were some additional medication safety sessions provided for some staff on a variety 
of topics.  
Documentation such as sign in sheets and ward lists provided assurance to hospital 
management regarding attendance. However, there was limited evidence of systems 
in place to monitor those who had, or had not, completed education sessions. It is 
the responsibility of managers to ensure that there is an appropriate method in place 
for the recording of all training. These records must be appropriately maintained and 
managed. 
Some hospitals with well-developed medication safety programmes had devised 
novel and innovative ways to provide education to front-line staff to supplement 
formal education sessions. Examples observed by inspectors in hospitals included; 
‘one minute’ tutorials§§§§§§§§§§§§§, 10 minute ward-based education sessions, 
lunchtime education sessions, e-learning programmes and medication safety 
newsletters.   
 
 
 
 
 
 
 
 
 
                                       
§§§§§§§§§§§§§ . ‘One minute’ tutorials involving a one minute presentation on one slide, circulated to staff 
through a variety of mediums, designed for multidisciplinary access to educational information.  
 
Medication safety monitoring programme overview report 
___________________________________________________________ 
  Health Information and Quality Authority 
 
87 
 
Staff induction 
All hospitals reported that nurses completed some elements of medication safety 
education on induction. The types of training included in nurses’ induction are 
outlined in the figure 12 below. 
 
Figure 12: Types of medication safety education included in induction for nurses.   
Almost all hospitals reported some form of medication safety training for non- 
consultant hospital doctors on induction, although the quantity and quality of the 
training varied across each hospital, some hospitals reported only 10 to 15 minutes 
allocated to medicines-related education on induction. To enhance staff education, 
some hospital pharmacy departments had provided additional medicines-related 
education sessions for non-consultant hospital doctors, but ensuring full attendance 
was identified as an ongoing challenge for the hospitals. 
Ongoing education 
No one method of providing education and information to staff has been proven to 
improve quality of healthcare; however, when a range of educational interventions 
are used together the effects may be improved.149,150,151 For example, a combination 
of individual, group and web-based training, discussion groups, conferences, local 
leaders, audit and incident feedback, educational material and reminders could 
support improvements in clinical care. HIQA observed a combination of these 
educational interventions in practice.      
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Awareness campaigns were untaken by some hospitals in relation to information on 
new medicines such as direct oral anticoagulants (DOAC). Inspectors were informed 
that these sessions were held during lunchtime meetings, grand rounds,************** 
nurses’ study days or ward-based education sessions.     
Two hospitals inspected had held medication safety awareness weeks where 
different elements of medication safety were highlighted each day via promotional 
stands and information sessions. In addition a number of hospitals inspected 
reported that they had held medication safety awareness days. 
A number of hospitals held multidisciplinary lunchtime education fora which included 
medication management topics; while another hospital facilitated ward-based 
medication safety awareness session and included medication issues and updates in 
the wards daily safety huddle.†††††††††††††† For example, a number of hospital 
informed inspectors that they used ‘safety huddles’ on the wards and in the 
pharmacy department to provide education sessions or updates to staff on specific 
topics relating to medication, to highlight areas for improvement and to encourage 
discussion around medication safety.  
In addition to education and training, inspectors were given an account of how some 
hospitals distributed information regarding medication safety. These included:  
§ newsletters and memos  
§ ward communication books  
§ meetings    
§ journal clubs 
§ grand rounds 
§ development of booklets for staff.  
Although all hospitals demonstrated evidence of medication management education 
at induction, with some additional education sessions, there was very limited 
evidence of structured ongoing medication safety education aligned to a medication 
safety programme.  
  
                                       
************** Grand rounds: are formal meetings where physicians and other clinical support and 
administrative staff discuss the clinical case of one or more patients. Grand rounds originated as part 
of medical training.   
†††††††††††††† Safety huddles: are brief and routine meetings for sharing information about potential or 
existing safety problems facing patients or workers. They aim to increase safety awareness among 
front-line staff, allow for teams to develop action plans to address identified safety issues, and foster 
a culture of safety. 
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Recommendation 
1. Hospitals must ensure healthcare professionals have the necessary 
competencies to deliver high-quality medication safety through induction and 
ongoing training. This should include a structured, targeted programme of 
education for medication safety aligned with the hospitals medication safety 
strategy.  
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3. Conclusion  
‘Medication without harm’ is the challenge set by the World Health Organization in 
its Global Patient Safety Challenge on Medication Safety. Part of this challenge 
involves global and national programmes for medication safety including strategies, 
guidelines, plans and tools to make medication use safer for patients. The challenge 
to the wider healthcare service means mobilising resources and clearly mapping out 
a vision for medication safety based on international research and best practice to 
ensure that patients are protected from harm.3 
To focus on this priority area for all public acute hospitals in Ireland, HIQA 
commenced a monitoring programme of medication safety in October 2016 and 
inspected 34 hospitals from this time to the end of 2017. During this monitoring 
programme HIQA identified significant variation between hospitals in relation to 
systems in place to support medication safety.  
To achieve medication safety, clear corporate and clinical governance arrangements, 
with a formal strategy to map out a programme for improving the medication 
management process is required. While HIQA found that the majority of hospitals 
had evidence of planning current and future medication safety activities, there is a 
need for all hospitals to outline future direction in relation to medication safety.  
While most hospitals had a Drugs and Therapeutics Committee, or formalised links 
with a committee located at a larger regional hospital, it is essential that all hospitals 
have a functioning Drugs and Therapeutics Committee to strengthen their 
governance arrangements and drive improvement in medication safety.  
Although many hospitals had invested dedicated resources, time and effort into 
clinical pharmacy services and medication safety programmes over a number of 
years, HIQA found disparities in clinical pharmacy services, both in how they were 
provided and resourced. Therefore, there is a requirement for national planning to 
target resourcing to ensure consistency in baseline clinical pharmacy service 
provision across all models of hospitals to ensure the safe use of medicines. While 
there may be a case for targeted investment in some hospitals, it is important that 
any investment is accompanied by a clear strategic vision of what needs to be 
achieved.  
Any evaluation of need should also be cognisant of the desired model of care to be 
adopted, and the key role that technology plays in driving efficiency and ensuring 
safety for patients. Should increased investment in clinical pharmacy resources be 
forthcoming, there will also need to be significant investment in support for clinical 
pharmacy management staff within Pharmacy Departments, through structured 
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training and peer support, to fully realise any potential benefits that might be 
expected.  
Patients and their families should be given information and educated about the 
medications they are prescribed so that they can protect themselves from harm. 
However, considerable variation in how patients were given information about new 
medicines across the hospitals inspected was identified both by the questionnaire 
distributed as part of this monitoring programme and in the findings of the first 
National Patient Experience Survey 2017.111 Hospitals must ensure that patients 
receive appropriate information in relation to their medicines. 
While HIQA identified the existing presence of some collaboration and cooperation 
between hospitals during this monitoring programme, there is much more potential 
for this to yield benefits, especially within the framework of hospital groups.  All 
healthcare providers, hospital managers and clinical leaders should work together to 
ensure evidence-based improvements are implemented and that learning is shared 
with the wider healthcare system in the interests of patient safety. It is 
recommended that individual hospitals should also look to engage with their peer 
hospitals in working to address similar improvement priorities. 
Key to future developments is progressing eHealth and the use of technology to 
drive improvement and reduce human error in busy, complex and challenging 
environments. Inspection teams observed where hospitals had implemented 
technology-driven medication safety quality improvements. Many of these projects if 
shared could at local, regional and national level rapidly improve patient safety. 
Overall, during this monitoring programme HIQA observed many examples of good 
practices and medication safety initiatives, driven by dedicated hospital staff, 
managers and clinicians who were committed to improving patient safety. This 
considerable body of work should be shared to improve patient safety and reduce 
variation throughout the Irish healthcare system, but requires commitment and 
effective planning to build on the progress achieved by individual hospitals to date.  
Strategic national planning and targeted investment is required to achieve genuine 
system improvement for patients and meet the challenge of medication without 
harm. 
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4. Glossary of terms  
This glossary details key terms and a description of their meaning within the context 
of this document.  
Accountability: being answerable to another person or organisation for decisions, 
behaviour and any consequences.  
Acute services: hospital-based healthcare services for inpatients, outpatients and 
people having day-case treatments. 
Adverse drug reaction: a response to a medicine which is noxious and 
unintended, and which occurs at doses normally used in humans for the prevention, 
diagnosis, or treatment of disease. 
Anticoagulant: a medicine that is commonly referred to as blood thinners that 
prevent or treat blood clots, but these medicines also carry an increased risk of 
bleeding or clots, so patient education and regular monitoring of blood levels are 
essential to maintain patient safety and ensure good patient outcomes.   
Assurance: being sure or certain about systems, processes and procedures and 
standing over business objectives. It involves monitoring risk and implementing 
controls to mitigate that risk.  
Audit: a quality improvement process that seeks to improve service-users care and 
outcomes through systematic review of care against explicit criteria and the 
implementation of change. 
Automation: is the method of making a machine, a process, or a system work 
without being directly controlled by a person. 
Best practice: clinical, scientific or professional practices that are recognised by a 
majority of professionals in a particular field. These practices are typically evidence 
based and consensus-driven. 
Best possible medication history: A standardised method of collecting and 
documenting an accurate current list of prescribed and non prescribed medication 
for an individual patient using as many sources of information as possible.  
Clinical Audit: a quality improvement process that seeks to improve care and 
outcome through systematic review of care against explicit criteria and the 
implementation of change.  
Clinical governance: a system through which service providers are accountable for 
continually improving the quality of their clinical practice and safeguarding high 
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standards of care by creating an environment in which excellence in clinical care will 
flourish. This includes mechanisms for monitoring clinical quality and safety through 
structured programmes, for example, clinical audit.  
Clinical guidelines: systematically developed statements, based on a thorough 
evaluation of the evidence, to assist healthcare professional and patient decisions 
about appropriate healthcare for specific circumstances, across the entire clinical 
spectrum. 
Clinical nurse specialist: a nurses with specially focused knowledge and skills, 
required to improve the quality of patient care with a clinical focus on assessment, 
planning, delivery and evaluation of care given to patients and their families.  
Clinical pharmacist: qualified pharmacist who develops and promotes the rational, 
safe and appropriate medication usage. 
Clinical pharmacy service: describes the activity of pharmacy teams in ward and 
clinic settings. 
Corporate governance: the system by which services direct and control their 
functions in order to achieve organisational objectives, manage their business 
processes, meet required standards of accountability, integrity and propriety and 
relate to external stakeholders. 
Culture: the shared attitudes, beliefs and values that define a group or groups of 
people and shape and influence perceptions and behaviours. 
Decision support tools: are resources that provide guidance or incorporate 
knowledge to help clinicians make the most appropriate clinical decision for patient 
care. 
Direct oral anticoagulants (DOAC): medications used to treat or prevent blood 
clots. However, there is a potential for bleeding with their use or clotting leading to 
stroke with missed doses. Options for anticoagulation have been expanded recently 
with the introduction of new anticoagulants called direct oral anticoagulants 
Dispensing: involves the preparation, packaging, labelling, record keeping, and 
transfer of a prescription medication to a patient or an intermediary (such as a nurse 
or doctor), who is responsible for administration of the medication. 
Drugs and therapeutics committee: a multidisciplinary group of people from 
within and outside a hospital or group of hospitals, which reports to senior 
management. The committee is responsible for expert governance, oversight and 
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review of the service to ensure safe and effective medication usage in the hospital or 
hospitals in question.  
Effective: a measure of the extent to which a specific intervention, procedure, 
treatment, or service, when delivered, does what it is intended to do for a specified 
population. 
Efficient: use of resources to achieve best results with minimal waste. 
Electronic Health (eHealth): involves the integration of all information and 
knowledge sources involved in the delivery of healthcare via information technology-
based systems. eHealth Ireland was established by the Department of Health in 
2015 to focus on the promotion and implementation of an eHealth agenda across 
the Irish Health Service. It is managed through the Office of the Chief Information 
Officer. 
Electronic prescribing and administration record: computerised system which 
facilitates the communication of prescriptions enabling prescriptions to be reviewed 
modified and generated with better oversight of medication management processes. 
The system supports legible and complete prescriptions and facilitates better 
communication, traceability, audit, improved access for prescribers and potential 
savings on costs and resources.  
Forcing functions: are design processes so errors are virtually impossible to make, 
for example removal of a product from use such as potassium. 
Formulary: a managed list of preferred medicines that have been approved by the 
hospital’s Drugs and Therapeutics Committee for use at the hospital. Use of a 
formulary ensures governance oversight of the introduction and ongoing use of 
medicines in practice at the hospital, and in doing so ensures an appropriate level of 
management control over medicines use, in the interest of both patient safety and 
financial management. 
Grand rounds: formal meetings where physicians and other clinical support and 
administrative staff discuss the clinical case of one or more patients. Grand rounds 
originated as part of medical training.   
Governance: in healthcare, an integration of corporate and clinical governance; the 
systems, processes and behaviours by which services lead, direct and control their 
functions in order to achieve their objectives, including the quality and safety of 
services for service users. See also Clinical governance and Corporate 
governance above. 
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Harm: impairment of structure or function of the body and or any detrimental effect 
arising from this, including disease, injury, suffering, disability and death. Harm may 
be physical, social or psychological. The degree of harm relates to the severity and 
duration of harm, and the treatment implications, that result from a patient safety 
incident. Degrees or levels of harm include:  
§ None — service-user outcome is not symptomatic or no symptoms have been 
detected and no treatment is required.  
§ Mild — service-user outcome is symptomatic, symptoms are mild, loss of function 
or harm is minimal or intermediate but short term, and no or minimal 
intervention (for example, extra observation, investigation, review or minor 
treatment) is required.  
§ Moderate — service-user outcome is symptomatic, requiring intervention (for 
example, additional operative procedure or additional therapeutic treatment), an 
increased length of stay, or causing permanent or long-term harm or loss of 
function.  
§ Severe — service-user outcome is symptomatic, requiring life-saving intervention 
or major surgical or medical intervention, shortening life expectancy or causing 
major permanent or long-term harm or loss of function.  
§ Death — on balance of probabilities, death was caused or brought forward in the 
short-term by the incident.  
Healthcare: services received by individuals or communities to promote, maintain, 
monitor or restore health. 
Health Service Executive (HSE): provider and or funder of all of Ireland's public 
acute healthcare services or any subsequent agency that takes on the HSE’s 
statutory functions. 
High-risk medications: medicines that bear a heightened risk of causing 
significant patient harm when they are not used correctly. Errors with these 
medicines may not be more common than those from other groups but their 
consequences can be more devastating as they have smaller margins of safety than 
other medications and therefore warrant particular caution in their handling. These 
are also known as ‘High-Alert’ Medications.  
Hospital Groups: the hospitals in Ireland are organised into Seven Hospital 
Groups. 1. Ireland East Hospital Group. 2. Dublin Midlands Hospital Group. 3. 
South/South West Hospital Group 4. Saolta Hospital Group. 5. University Limerick 
Hospitals Group. 6. RCSI Hospitals Group. 7. National Children’s Hospital Group. The 
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services delivered include inpatient scheduled care, unscheduled/emergency care, 
maternity services, outpatient and diagnostic services. The Group Chief Executive of 
each Hospital Group reports to the National Director for Acute Services and is 
accountable for their Hospital Groups planning and performance under the HSE 
Accountability Framework. 
Indicators are measurement tools, screens, or flags that are used as guides to 
monitor, evaluate, and improve the quality of patient care, clinical support services, 
and organisational function that affect patient outcomes. 
Information and communication technology (ICT): the tools and resources 
used to communicate, create, disseminate, store and manage information 
electronically. 
Intravenous medication monographs: an approved set of standardised and 
approved instructions for the correct preparation and administration of intravenous 
medication, that have been designed to reduce the risk of error, and that are 
specifically tailored to the intravenous medicines stocked within the hospital.  
Just culture: an environment which seeks to balance the need to learn from 
mistakes and the need to take disciplinary action.  
Key performance indicator: specific and measurable elements of practice that 
can be used to assess quality and safety of care. 
Latent failure: a failure that lies dormant in the system, usually removed from the 
direct control of the practitioner that may or may not become an active error. 
Medication incident: any preventable event that may cause or lead to 
inappropriate medication use or patient harm while the medication is in the control 
of the healthcare professional, patient, or consumer. Such events may be related to 
professional practice, healthcare products, procedures, and systems, including 
prescribing, order communication, product labelling, packaging, and nomenclature, 
compounding, dispensing, distribution, administration, education, monitoring, and 
use. 
Medication management:  clinically-effective cost-effective and safe use of 
medicines to ensure that service users get the maximum benefit from the medicines 
they need while at the same time minimising the potential harm.   
Medication management process:  including; selection, procuring storing, 
ordering, prescribing, transcribing, distribution, preparing, dispensing, administration 
documentation, reconciliation, monitoring and disposal of medications  
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Medication reconciliation: involves using a systematic process to obtain an 
accurate and complete list of all medications taken prior to admission, discharge and 
other transitions in care.   
Medication safety: freedom from preventable harm with medication use. 
Medication safety officer: a clinical practitioner designated by the hospital to 
serve as the authoritative expert in safe medication use. 
Medications optimisation: a person-centred approach to safe and effective use of 
medications, to ensure people obtain the best possible outcomes from their 
medications. Medications optimisation differs from medication management in a 
number of ways with a focus on outcomes and patients rather than process and 
systems. 
Medication safety programme: a programme designed to drive best practice in 
medication safety by guiding and collaborating with healthcare professionals 
involved in the medication use process in order to proactively assess and minimise 
patient risk, and implement quality initiatives to eliminate avoidable harm from 
medication. 
Metrics: parameters or measures of quantitative assessment used for measurement 
and comparison or to track performance.  
Model 1, 2, 3 and 4 hospitals: in 2010, the HSE’s National Acute Medicine 
Programme described four generic acute hospital models (model 1, 2, 3 and 4). 
Their purpose was to define the level of service that can be safely provided at acute 
hospitals within the constraints of available facilities, staff, resources and local 
factors. 
Model-1 hospitals are community and or district hospitals and do not have 
surgery, emergency care, acute medicine (other than a select group of low-risk 
patients) or critical care. 
Model-2 hospitals can provide the majority of hospital activity including extended 
day surgery, selected acute medicine, local injuries, a large range of diagnostic 
services, including endoscopy, laboratory medicine, point-of-care testing, and 
radiology – computed tomography (CT), ultrasound and plain-film X-ray – specialist 
rehabilitation medicine and palliative care. 
Model-3 hospitals admit undifferentiated acute medical patients; provide 24-seven 
acute surgery, acute medicine, and critical care. 
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Model-4 hospitals are tertiary hospitals and are similar to model-3 hospitals but 
also provide tertiary care and, in certain locations, supra-regional care. 
Monitoring: systematic process of gathering information and tracking change over 
time. Monitoring provides a verification of progress towards achievement of 
objectives and goals.  
Multidisciplinary: an approach to the planning of treatment and the delivery of 
care for a service user by a team of healthcare professionals who work together to 
provide integrated care. 
National incident management system:  National Incident Management System 
(NIMS) is a risk management system that enables hospitals to report incidents in 
accordance with their statutory reporting obligation to the State Claims Agency 
(Section 11 of the National Treasury Management Agency (Amendment) Act, 2000).  
Near miss: a near-miss incident is an incident which could have resulted in harm, 
but did not either by chance or timely intervention.  
Non-consultant hospital doctor: doctors that have not yet reached hospital 
consultant grade. Non-consultant hospital doctors include specialist registrars, 
registrars, senior house officers and interns.  
Open disclosure: an open, consistent approach to communicating with service 
users when things go wrong in healthcare. This includes expressing regret for what 
has happened, keeping the service user informed, providing feedback on 
investigations and the steps taken to prevent a reoccurrence of the adverse event. 
Patient: a person who is receiving healthcare or treatment (sometimes referred to 
as a service user). 
Patient safety: is the term used nationally and internationally to describe the 
freedom from unnecessary harm or potential harm associated with healthcare 
services and the reduction of risk of unnecessary harm to an acceptable minimum 
(World Health Organization, 2009).  
Patient safety incident: as defined in the Health Information and Patient Safety 
Bill Revised General Scheme (2015) a ‘patient safety incident’ means:  
a) any unintended or unanticipated injury or harm to a service user that 
occurred during the provision of a health service,  
b) an event that occurred when providing a health service to a service user 
that did not result in actual injury or harm but there are reasonable grounds 
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to believe that the event concerned placed the service user at risk of 
unintended or unanticipated injury or harm,  
c) an incident that was prevented from occurring due to timely intervention or 
chance and which there are reasonable grounds for believing could have 
resulted, if it had not been so prevented, in unintended or unanticipated 
injury or harm to a service user during the provision of a health service to 
that service user.  
Policy: a written operational statement of intent which helps staff make appropriate 
decisions and take actions, consistent with the aims of the service provider, and in 
the best interests of service users. 
Prophylaxis:  a medication or a treatment designed and used to prevent a disease 
from occurring.  
Quality improvement: a systematic approach using specific methods to improve 
quality through achieving successful and sustained improvement. 
Risk: the probability of danger, loss or injury within the healthcare system. Risk is 
the effect of uncertainty on objectives. It is measured in terms of consequences and 
likelihood.  
Risk assessment: refers to the overall process of risk analysis and risk evaluation. 
Its purpose is to develop agreed priorities for the identified risks. It involves 
collecting information through observation, communication and investigation. 
Risk management: the systematic identification, evaluation and management of 
risk. It is a continual process with the aim of reducing the risk of injury to patients, 
staff, and visitors and the risk of loss to the organisation itself.  
Risk Register: a risk register is a risk management tool. It acts as a central 
repository for all risks identified by an organisation and, for each risk includes 
information such as risk probability, impact controls and risk owner. 
Safety culture: an integrated pattern of individual and organisational behaviour, 
based upon shared beliefs and values, which continuously seeks to minimise service-
user harm which may result from the processes of care delivery.  
Safety huddles: brief and routine meetings for sharing information about potential 
or existing safety problems facing patients or workers. They aim to increase safety 
awareness among front-line staff, allow for teams to develop action plans to address 
identified safety issues, and foster a culture of safety.  
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Service user: a ‘service user’ refers to a person who uses healthcare (including 
mental health) services.  
Smart-pumps: computerised infusion devices with multiple safety features 
that include customised drug libraries, dose calculations based on programmed 
patient weights and the setting of dose limits.  
Strategic plan: a focused guide which outlines future direction for an organisation 
through the development of targets to achieve strategic goals. It generally projects a 
medium to long-term vision (three to five years) and enables the development of an 
operational plan, aligned to identify needs.  
System: a set of interdependent elements, both human and non-human, interacting 
to achieve a common aim. 
Staff: the people who work in, for or with the service provider. This includes 
individuals who are employed, self-employed, temporary, volunteers, contracted or 
anyone who is responsible or accountable to the organisation when providing a 
service to patients. 
Standard: describes the high-level outcome required to achieve a quality, safe 
service. 
Standard treatment guidelines or prescribing guides: these consist of 
systematically developed statements to help prescribers make decisions about 
appropriate treatments for specific clinical conditions. 
Terms of reference: a set of terms that describe the purpose and structure of a 
project, committee or committee. 
Transition of care is the movement of a patient from one setting of care to 
another. Settings of care may include hospitals, primary care, long-term care 
facilities, home health, and rehabilitation facilities. Transitions increase the risk of 
error due to the potential for miscommunication. 
Venous thromboembolism:  is a blood clots consists of deep veins thrombus  
DVT and pulmonary embolism (PE). Blood clots (thrombus) can form within deep 
veins (DVT) and these clots can fragment and travel to lungs leading to Pulmonary 
Embolism (PE).  
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6. Appendices 
Appendix 1 
List of hospitals inspected (in chronological order)  
Number Date of 
inspection 
Hospital 
 
Model of 
hospital 
 
1.  November 2016 Bantry General Hospital 2 
2.  November 2016 Connolly Hospital 3 
3.  November 2016 Mater Misericordiae University Hospital 4 
4.  November 2016 Naas General Hospital 3 
5.  December 2016 Nenagh Hospital 2 
6.  December 2016 Sligo University Hospital 3 
7.  December 2016 University Hospital Waterford 4 
8.  March 2017 Midland Regional Hospital Tullamore 3 
9.  March 2017 Rotunda Hospital  Specialist 
10. March 2017 St Michael's Hospital 2 
11. April 2017 National Maternity Hospital Specialist 
12. April 2017 Midland Regional Hospital Mullingar 3 
13. April 2017 St Vincent’s University Hospital 4 
14. May 2017 Galway University Hospital 4 
15. May 2017 Our Lady's Children's Hospital  Specialist 
16. May 2017 Tallaght Hospital 4 
17. May 2017 University Hospital Limerick 4 
18. June 2017 Kilcreene Orthopaedic Hospital  Specialist 
19. June 2017 Roscommon University Hospital 2 
20. June 2017 St Columcille's Hospital 2 
21. June 2017 St Luke’s Hospital, Rathgar Specialist 
22. July 2017 Cappagh National Orthopaedic Hospital Specialist 
23. July 2017 Mallow General Hospital 2 
24. July 2017 Portiuncula University Hospital 3 
25. July 2017  St James’ Hospital  4 
26. August 2017 Letterkenny University Hospital 3 
27. August 2017 Mayo University Hospital 3 
28. August 2017 Our Lady of Lourdes Hospital 3 
29. August 2017 South Infirmary Victoria University Hospital 2 
30. September 2017 Mercy University Hospital 3 
31. September 2017 Midlands Regional Hospital Portlaoise 3 
32. September 2017 Royal Victoria Eye and Ear Hospital Specialist 
33. October 2017 Coombe Women & Infants University Hospital Specialist 
34. October 2017 St Luke’s General Hospital, Kilkenny 3 
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Appendix 2: Monitoring methodology 
HIQA’s medication safety monitoring programme was planned to broadly follow 
three distinct phases (P1, P2, P3) as outlined in Figure A2.1 below. The rationale for 
using a phased approach was to allow and encourage incremental improvement in 
the systems in place in public acute hospitals. 
During the first phase, the findings of which are detailed in this report, HIQA focused 
on the fundamental governance and structure requirements to support a medication 
safety programme.  
  
 
Figure A2.1: Programme of monitoring and improving medication in acute hospitals 
In future phases, HIQA plans to build upon the approach taken in phase one and 
examine in further detail how hospitals have designed, implemented and are 
monitoring the ongoing effectiveness of defined medication safety processes and 
systems. Phase two will focus on how the medication safety systems operate in 
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practice to prevent latent failures contributing to medication error. Phase three will 
focus on medication optimisation.ccc Phase three will include a focus on how 
hospitals both involve patients, and mitigate risks associated with high-risk patient 
groups, high-risk medicines, high-risk clinical settings and transitions of care.  
This monitoring programme was guided by an expert advisory group which assisted 
with the development of the monitoring programme and methodology. Membership 
included representation from patient advocacy groups, clinicians and a number of 
national professional bodies with relevant expertise from across the Irish health 
service.  
Phase one monitoring methodology 
To assess whether hospitals had the basic foundations and structures to ensure an 
effective medication safety programme, phase one of HIQA’s medication safety 
monitoring programme:  
§ measured performance by carrying out announced on-site inspections in 
order to assess the structures and systems in place for medication 
management and safety. 
§ assessed if hospitals had the essential elements of a medication safety 
programme in place, with a particular focus on governance of medication 
safety, risk management, audit and evaluation of practice, policies, 
procedures and guidelines, access to information, staff training and patient 
information. 
§ established if hospitals had effective and safe medication management 
systems in place to ensure patient safety in line with international best 
practice and research. 
§ provided hospitals with the findings of the inspections to highlight 
examples of good practice and areas for improvement.  
§ published the findings of inspections on our website www.hiqa.ie.  
The focus for phase one inspections was outlined in seven lines of enquiry, which 
were developed based on international best practice and research, and were aligned 
to the National Standards.12  
These lines of enquiry were initially published and communicated to hospitals in 
October 2016 ahead of onsite inspections in HIQA’s ‘Guide to the Health Information 
and Quality Authority’s Medication Safety Monitoring Programme in Public Acute 
                                       
ccc Medication optimisation is defined as 'a person-centred approach to safe and effective use of 
medications, to ensure people obtain the best possible outcomes from their medications’. 
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Hospitals’ (available on HIQA’s website https://www.hiqa.ie/reports-and-
publications/guide/guide-medication-safety-monitoring-acute-hospitals).  
This guide also gave hospitals required information on the inspection and monitoring 
process. 
Lines of enquiry and associated standards from the National Standards for 
Safer Better Healthcare 
Area to be 
explored 
Line of enquiryddd National 
Standards for 
Safer Better 
Healthcare 
Clear lines of 
accountability and 
responsibility for 
medication safety  
Patient safety is enhanced through an 
effective medication safety programme 
underpinned by formalised governance 
structures and clear accountability 
arrangements.  
3.1, 5.1, 5.2, 5.4, 
5.5, 5.6, 5.8, 5.9, 
5.10, 7.1 
Patient involvement in 
service delivery 
Patients and or carers are informed about the 
benefits and associated risks of prescribed 
medicines in a way that is accessible and 
understandable.  
1.4, 1.5, 1.7, 3.1, 
4.1 
Policies procedures 
and guidelines 
Hospitals develop effective processes to 
promote medication safety that are 
implemented and supported by clear and up-
to-date policies, procedures and or protocols. 
2.1, 3.1, 3.2, 3.3, 
3.5, 3.6, 3.7, 5.8, 
5.11, 8.1 
Risk management There are arrangements in place to identify, 
report and manage risk related to medication 
safety throughout the hospital.  
3.1, 3.2, 3.3, 3.5, 
3.6, 3.7, 5.8, 5.10, 
5.11, 8.1 
Audit and evaluation The effectiveness of medication management 
systems are systematically monitored and 
evaluated to ensure they are effective. 
2.8, 3.1, 5.8, 8.1 
Education and 
training 
Safe prescribing and drug administration 
practices are supported by mandatory and 
practical training on medication management 
for relevant staff. 
6.2, 6.3  
Access to information Essential information of the safe use of 
medications is readily available in a user-
friendly format and is adhered to when 
prescribing, dispensing and administering 
medications. 
2.5, 8.1 
 
 
 
                                       
ddd Lines of enquiry are the key questions or prompts that inspectors use to help inform their inspection, assessment or 
investigation. 
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Before inspection 
Hospitals were given 10 days written notice of announced inspections and requested 
to complete a pre-inspection information request and return to HIQA within five 
working days. The reason for conducting an announced inspection was that 
inspectors needed to meet with key hospital personnel, such as the Chair of the 
hospital’s Drugs and Therapeutics Committee that may not be available if the 
inspection was unannounced. HIQA also requested copies of the following to be 
submitted to HIQA in advance of inspections, if available: 
§ most recent medication safety programme plan and annual plan, 
§ new medicines application request form,  
§ Drugs and Therapeutics Committees terms of reference and minutes from the 
previous twelve months, 
§ an organogram clearly showing the lines of communication and cooperation 
between the hospital’s Drugs and Therapeutics Committee and or Medication 
Safety Committee, the pharmacy department, the risk management team and 
or department and the hospital’s senior management team.  
The purpose of the pre-inspection information request was to provide the inspection 
team with baseline information about the hospital’s medication safety programme 
and the governance in place for medication safety.  
Before the inspection, inspectors reviewed key pieces of information relating to the 
hospital such as previous inspection reports, any relevant information received by 
HIQA relating to the hospitals, and other available published data. Particular issues 
that may have needed to be addressed during the inspection were discussed by the 
inspection team in preparation for the inspection. 
To enable the effective operation of inspections hospitals were provided with a 
provisional inspection timetable, which outlined the personnel required for interview 
on the day.  
The inspection process 
On the day of the announced inspection, the inspection team contacted the 
hospital’s Chief Executive Officer (CEO) and or General Manager on arrival at the 
hospital reception and met with the relevant hospital representatives. The inspection 
team began by outlining the purpose of the inspection and the plan for the day. 
Inspectors requested a list of additional documentation for review and requested 
that anonymous patient surveys be distributed to a small number of patients in the 
outpatient’s clinic. The survey was offered to patients who were discharged from the 
hospital within the past year on regular medications.  
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Hospital management were informed that during the course of the day’s inspection, 
inspectors would gather evidence relevant to medication safety through interviews 
with senior management and front-line staff, general observation in clinical areas, 
patient surveys and review of documentation at both ward and senior management 
levels.  
Management were advised that if during the course of the inspection any specific 
risks were identified (that inspectors believe presented a risk to the health or welfare 
of patients) these would be escalated in line with HIQA’s escalation process 
(Appendix 3 and 4).  
Details on key findings from the inspection were communicated by the inspection 
team to hospital management on completion of the inspections. In addition, any 
specific risks identified by the inspection team were communicated to senior 
management and the hospital’s CEO and or general manager.   
Where high risks were identified, the hospital was notified in writing within two days 
of the inspection and requested to formally report back to HIQA within five working 
days with an action plan detailing how the hospital were mitigating and managing 
these identified risks. Senior management in the Health Service Executive (HSE) 
were also notified in writing of identified risks.  
A draft report detailing the findings from the inspection was returned to each 
hospital for a factual accuracy check, and final reports were subsequently published 
on HIQA’s website.  
Inspection teams conducted on-site monitoring in 34 hospitals in a variety of hospital 
models and geographical areas. Selection of sites (for inspection) was planned 
considering other HIQA monitoring activity to minimise hospitals having inspections 
by different HIQA programmes within a short period of time. 
During the course of the inspections, HIQA identified specific issues in six hospitals 
that they believed presented a risk to the health or welfare of patients as 
summarised in Appendix 5. These were communicated verbally during the 
inspections, in writing to the hospitals immediately following inspection and detailed 
in individual hospital reports.  
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Appendix 3: HIQA Risk Escalation Process Map 
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Appendix 4: Risk matrix 
Risk assessment process: the authorised persons will assess the consequence of 
the risk to patients and the probability of reoccurrence to determine the level of risk, 
using the tables below. The consequence of the risk and the probability of 
occurrence are both assessed and given a score from 1 to 5. The risk matrix is then 
used to give an overall risk score. This score then corresponds with the classification 
of risk table. 
Consequence of the risk: what is the actual impact of the risk? 
Consequence 
category 
Impact on individual/future patients 
1 Negligible No obvious harm 
No injury requiring treatment 
2 Minor Minor injury 
No permanent harm 
3 Moderate Significant injury or ill health 
Some temporary incapacity 
4 Major 
 
Major injuries or long-term incapacity or disability 
Major permanent harm as result of clinical or non-clinical 
incident injuries or long-term incapacity or disability 
Major permanent harm 
5 Catastrophic Death 
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Probability of reoccurrence: what is the chance of this event occurring or 
reoccurring? Identify the ‘probability rating’ for reoccurrence from the following 
table: 
Probability 
Score 
Descriptor Frequency 
1 Rare This will probably never happen or 
reoccur 
2 Unlikely Do not expect it to happen or reoccur 
again but it is possible 
3 Possible Might happen or reoccur occasionally 
4 Likely Will probably reoccur, but it is not a 
persistent issue 
5 Almost certain Will undoubtedly reoccur, possibly 
frequently 
 
The lead authorised person classifies the risk using the risk matrix below and 
documents the findings that indicate the risk.  
Risk Matrix 
Probability Consequence category 
 
 Negligible 
(1) 
Minor 
(2) 
Moderate 
(3) 
Major 
(4) 
Catastrophic 
(5) 
Almost certain (5) 5 10 15 20 25 
Likely (4) 4 8 12 16 20 
Possible (3) 3 6 9 12 15 
Unlikely (2) 2 4 6 8 10 
Rare (1) 1 2 3 4 5 
 
The risk is then classified as high, moderate, low or very low as per the risk matrix 
score. See classification of risk table below.  
 
  
Classification of risk  Risk matrix score 
 High risk (red) 15, 16, 20 or 25 
Moderate risk (orange) 8, 9, 10 or 12 
Low risk  (yellow) 4, 5 or 6 
Very low risk  (green) 1, 2 or 3 
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Appendix 5:  
Risks identified  
The risks identified during the medication safety monitoring programme in 
November 2016 to October 2017 are detailed below. These were escalated at the 
time of inspection as per HIQA escalation process. 
Hospital 
name (in 
chronological 
order) 
Summary of risk(s) identified by HIQA  
 
Bantry General 
Hospital 
 
HIQA identified a specific issue related to:  
Compatibility checking prior to the sharing of intravenous drug 
administration guidance documentation with another hospital. 
 
Letterkenny 
University 
Hospital 
 
HIQA identified an immediate high risk at the hospital related to a relative 
lack of leadership, governance and management of medication safety 
related risk at the hospital. 
 
Midland 
Regional 
Hospital, 
Mullingar  
 
HIQA identified a composite of medication safety related risks at the 
hospital that may collectively present a serious risk to the health or welfare 
of patients, and immediate measures needed to be put in place to mitigate 
these risks. 
 
The immediate risks related to: 
 
§ An identified relative lack of effective systems in place to ensure 
minimum standards of safety and quality are met relating to 
medication safety. In addition, the hospital had failed to act to fully 
address risks previously identified and communicated by HIQA to 
the hospital following an inspection related to antimicrobial 
stewardship in November 2015 relating to: 
- the ongoing lack of a Clinical Pharmacy service  
- the lack of up-to-date approved set of intravenous product 
information monographs 
- the ongoing presence of potentially conflicting reference 
information in the ward setting relating to advice in the 
reconstitution and administration of intravenous medication.  
In addition, in reviewing the totality of findings from the inspection, the 
inspection team had determined that the current approach at the hospital 
to the leadership, governance and management of medication safety 
related risk was not sufficiently effective and represented a potential risk to 
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patients. The risks concerned included: 
§ The absence of strategic medication safety and operational plans 
detailing the development, implementation and maintenance of 
hospital wide medication safety systems.  
§ Inadequate arrangements in place to identify report and manage 
risks associated with medication use. 
§ An ongoing absence of a drug formulary to ensure that there are 
robust and transparent criteria for adopting, removing or updating 
the hospital’s drug prescribing list. 
§ A relative lack of current policies, protocols, and guidelines to 
support relevant clinical staff in safe prescribing and administration 
of medications at ward level. 
 
 
St Luke’s 
General 
Hospital, 
Kilkenny 
 
HIQA identified specific risks related to:  
§ the accommodation of paediatric patients undergoing medical 
assessment in an ancillary room with unsecure access to 
medications , clean and sterile consumables including needles, 
syringes, intravenous cannulae and sharps waste disposal bins   
§ preparation of intravenous medications within the patient zone. 
 
 
University 
Hospital 
Limerick 
 
HIQA identified a composite of medication safety related risks at the 
hospital that need to be collectively and comprehensively addressed.   
The inspection identified an underdeveloped approach to medication safety 
at the hospital, and an apparent ongoing fragmented approach to 
leadership, governance and management of medication related risk across 
the group through the group Drugs and Therapeutics Committee.  
The risks concerned included: 
§ inadequate arrangements in place to identify, report and manage 
risks associated with medication use - this results in poor 
awareness and underreporting of medication errors and near 
misses 
§ a lack of a cohesive approach to governance and oversight on the 
provision of pharmacy services to the five sites within the group 
§ poor compliance by the hospital Drugs and Therapeutic Committee 
with its own terms of reference 
§ the absence of an overarching strategy for medication safety, and 
associated operational plans detailing the development, 
implementation and maintenance of hospital wide medication 
safety systems.  
§ a relative lack of current policies, procedures, protocols and 
guidelines to support relevant clinical staff in safe prescribing and 
administration of medications at ward level. 
§ limited Clinical Pharmacy services, and the lack of formalised 
medication reconciliation process  
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§ the absence of an evidence based local formulary of medications  
accepted for use in the organisation. 
 
Notwithstanding these identified areas in need of improvement, Authorised 
Persons also identified more recent efforts to try to reconfigure the role 
and functioning of the Drugs and Therapeutics Committee, including new 
leadership of this committee. Moreover, HIQA acknowledged the intention 
to try to harmonise medication safety efforts through a group approach to 
governance.  
 
 
University 
Hospital 
Waterford 
 
HIQA identified a specific issue that may present a serious risk to the 
health or welfare of patients, and immediate measures need to be put in 
place to mitigate this risk. The immediate risk identified related to:  
§ The availability of outdated and potentially conflicting reference 
information in clinical areas relating to advice in the reconstitution 
and administration of intravenous medication 
 
During the course of onsite observation by authorised persons on three 
wards, it was observed that nurses continued to use different versions of 
legacy IV medication reference posters. This represents a risk as these 
were not current approved information sources, and it is possible that the 
instructions on the posters may not be compatible with the intravenous 
medicines currently used in the hospital. The hospital must ensure that out 
of date intravenous drug administration information in clinical areas are 
immediately retrieved and replaced throughout the facility with updated 
and standardised versions. 
 
In addition, in reviewing the totality of findings from the inspection, the 
inspection team has determined that the current approach at the hospital 
to the leadership, governance and management of medication safety 
related risk is ineffective and represents a risk to patients. The risks 
concerned include: 
§ The absence of strategic and operational plans detailing the 
development, implementation and maintenance of hospital wide 
medication safety systems.  
§ Inadequate arrangements in place to identify, report and manage 
risks associated with medication use. 
§ A lack of systematic monitoring and evaluation of the effectiveness 
of medication management systems to ensure they are effective. 
§ A relative lack of policies, procedures, protocols and guidelines to 
support medical staff in safe prescribing and administration of 
medications. 
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Appendix 6: National Coordinating Council for Medication Error 
Reporting and Prevention. Index for Categorising Medication 
Errors 
 
 
 
 
© 2001 National Coordinating Council for Medication Error Reporting and Prevention. All Rights 
Reserved. 
* Permission is hereby granted to reproduce information contained herein provided that such 
reproduction shall not modify the text and shall include the copyright notice appearing on the pages 
from which it was copied. 
 
  
Definitions 
Harm 
Impairment of the 
physical, emotional, or 
psychological function or 
structure of the body 
and/or pain resulting 
there from. 
Monitoring 
To observe or record 
relevant physiological 
or psychological signs. 
Intervention 
May include change 
in therapy or active 
medical/surgical 
treatment. 
Intervention 
Necessary to 
Sustain Life 
Includes cardiovascular 
and respiratory support 
(e.g., CPR, defibrillation, 
intubation, etc.) 
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Appendix 7: Hierarchy of effectiveness of risk reduction 
strategies in medication safety 
 
  
Reprinted with permission from ISMP Canada. 
 
Medication Safety Monitoring Programme Overview Report 
___________________________________________________________ 
  Health Information and Quality Authority 
 
  131 
 
  
Medication safety monitoring programme overview report 
___________________________________________________________ 
Health Information and Quality Authority 
 
132 
 
 
 
 
 
 
  
For further information please contact: 
Health Information and Quality Authority 
Dublin Regional Office 
George’s Court 
George’s Lane 
Smithfield 
Dublin 7 
Phone: +353 (0) 1 814 7400 
Email: qualityandsafety@hiqa.ie 
URL: www.hiqa.ie 
© Health Information and Quality Authority 2018 
